DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  1 
CONFIDENTIAL  
 A Randomized, Double -Blind, Placebo -Controlled Trial of TOL -463 Insert  for Suppression 
of Bacterial Vaginosis (BV)  [SUBVert]  
DMID Protocol Number:   18-0017  
DMID Funding Mechanism:  
Contract – HHSN2722013000121   
Task Order – HHSN27200 0016 
 Pharmaceutical Support:   Toltec Pharmaceuticals LLC  
IND Sponsor:   NIAID  
Lead Principal Investigator:   [INVESTIGATOR_308906] M arrazzo, MD, MPH  
DMID Clinical Project Manager :  Jonathan Glock, MPH  
Version Number:  5.0 
09 Decem ber 2020  
 
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  2 
CONFIDENTIAL  
 STATEMENT OF ASSURANCE  
Each Institution will hold a current Federal Wide Assurance (FWA) issued by [CONTACT_651118] (OHRP) for federally -funded human subjects research.  Each FWA 
will designate at least one Institutional Review Board (IRB)/Inde pendent Ethics Committee 
(IEC) registered with OHRP, for which  the research will be reviewed and approved by [CONTACT_5040]/IEC and will be subject to continuing review [45 CFR 46.103(b)]. The IRB/IEC designated 
under an FWA may include an institution’s IRB/IEC, an independent IRB/IEC, or an IRB/IEC of 
another institution  after establishing a written agreement with that other institution.  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  3 
CONFIDENTIAL  
 STATEMENT OF COMPLIANCE  
The study  trial will be carried out in accordance with Good Clinical Practice (GCP)  and as 
required by [CONTACT_716]:  
• [LOCATION_002] Code of Federal Regulations (CFR) 45 CFR Part 46 : Protection of Human 
Subjects  
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50  (Protection 
of Human Subjects) , 21 CFR Part 54 (Financ ial Disclosure by [CONTACT_6230]) , 21 
CFR Part 56 (Institutional Review Boards) , 21 CFR Part 11, and 21 CFR Part 312  
(Investigational New Drug Application ) 
• International Conference on Harmoni sation , (ICH) : Good Clinical Practice ( ICH E6 ); 62 
Federa l Register [ZIP_CODE] (1997); and future revisions  
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research, Report of the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research  
• National Institutes of Health (NIH) Office of Extramural Research  (OER) , Research 
Involving Human Subjects, as applicable  
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award , as 
applicable  
• Applicable Federal, State, and Loc al Regulations and Guidance  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  4 
CONFIDENTIAL  
 SIGNATURE [CONTACT_140180], including all statements regarding confidentiality, and 
according to local lega l and regulatory requirements and applicable US federal regulations and 
ICH E6 Good Clinical Practice (GCP)  guidelines.  
I agree to conduct the study in compliance with GCP and applicable regulatory requirements.  
I agree to conduct the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except when 
necessary to protect the safety, rights, or welfare of participant s. 
Principal Investigator  [INVESTIGATOR_651084] : 
 
Signed:   Date:   
 Jeanne Marrazzo, MD, MPH  
University of Alabama at Birmingham    
 
Site Investigator : 
 
Signed:   Date:   
 Harold C. Wiesenfeld , MD, CM 
University of Pi[INVESTIGATOR_651085] 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  5 
CONFIDENTIAL  
 Site Investigator : 
 
Signed:   Date:   
 Audrey French , MD  
Cook County Health    
 
Site Investigator : 
 
Signed:   Date:   
 Sheldon Morris , MD, MPH  
UC San Diego AntiViral Research Center (AVRC)    
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873224] OF ABBREVIATIONS  ................................ ................................ ................................ ........ 13 
PROTOCOL SUMMARY  ................................ ................................ ................................ ............. 17 
 KEY ROLES ................................ ................................ ................................ ......................... 21 
 BACKGROUND AND SCIEN TIFIC RATIONALE  ................................ .......................... 22 
 Background  ................................ ................................ ................................ ................. 22 
 Scientific Rationale  ................................ ................................ ................................ .....22 
2.2.1  Purpose of Study  ................................ ................................ ............................ 22 
2.2.2  Purpose of Study  ................................ ................................ ............................ 23 
2.2.3  Study Population  ................................ ................................ ............................ 23 
 Potent ial Risks and Benefits  ................................ ................................ ....................... 23 
2.3.1  Potential Risks  ................................ ................................ ............................... 23 
 Potential Risks Associated with TOL -463 ................................ .......24 
2.3.2  Potential Benefits  ................................ ................................ ........................... 24 
 STUDY DESIGN, OBJECTIVES AND ENDPOINTS OR OUTCOME MEASURES  .....25 
 Study Design Description  ................................ ................................ ........................... 25 
 Study Objectives  ................................ ................................ ................................ ......... 26 
3.2.1  Primar y ................................ ................................ ................................ ........... 26 
3.2.2  Secondary  ................................ ................................ ................................ .......26 
3.2.3  Exploratory  ................................ ................................ ................................ ....26 
 Study Endpoints  ................................ ................................ ................................ .......... 27 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  7 
CONFIDENTIAL  
 3.3.1  Primary Endpoint  ................................ ................................ ........................... 27 
3.3.2  Secondary Endpoints  ................................ ................................ ..................... 27 
3.3.3  Exploratory Endpoint  ................................ ................................ ..................... 27 
 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT  ................................ ......... [ADDRESS_873225] Storage and Stability  ................................ ................................ ......... 28 
 Acquisition/Distribution  ................................ ................................ ............................. 29 
 Dosage, Preparation, Dispensing and Administration of Study 
Intervention/Investigational Product ................................ ................................ ......... 30 
 Accountability Procedures for the Study Intervention/Investigational Product(s)  .....30 
 SELECTION OF PARTICIPANTS AND STUDY ENROLLMENT AND 
WITHDRAWAL  ................................ ................................ ................................ .................. 32 
 Eligibility Criteria  ................................ ................................ ................................ .......32 
5.1.1  Participant Inclusion Criteria  ................................ ................................ ......... 32 
 Screening Visit(s) Inclusion Criteria:  ................................ ............... 33 
 Enrollment Visit Inclusion Criteria:  ................................ ................. 34 
5.1.2  Participant Exclusion Criteria  ................................ ................................ ........ 34 
 Screening Visit(s) Exclusion Criteria:  ................................ .............. 35 
 Enrollment Visit Exclusion Criteria:  ................................ ................ [ADDRESS_873226]  ................................ ..................... 37 
5.2.2  Participant Replacement  ................................ ................................ ................ 38 
5.2.3  Study Termination  ................................ ................................ ......................... 38 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  8 
CONFIDENTIAL  
 
 STUDY PROCEDURES  ................................ ................................ ................................ ......39 
 Visit 0 (Day -15 to -8) Screening  ................................ ................................ ............... 39 
 Visit 1 (Day 1) Enrollment  ................................ ................................ ......................... 40 
 Planned Study Visits  ................................ ................................ ................................ ...42 
6.3.1  Visit 2 (Day 29 [Window:  Days 29 -35]) Follow -up ................................ .....42 
6.3.2  Visit 3 (Day 57 [Window:  Days 57 -63]) Follow -up ................................ .....43 
6.3.3  Visit 4 (Day 85 [Window:  Days 85 -91]) Follow -up (TOC)  ......................... 44 
6.3.4  Early Termination Visit  ................................ ................................ ................. 45 
 Unscheduled Study Visits  ................................ ................................ ........................... 46 
 Protocol Deviations  ................................ ................................ ................................ ....47 
 DESCRIPTION OF CLINICAL AND LABORATORY EVALUATIONS  ....................... 48 
 Clinical Evaluations  ................................ ................................ ................................ ....48 
7.1.1  Assessment of Concomitant Medications/Treatments other than Study 
Product  ................................ ................................ ................................ ........... 49 
7.1.2  Assessment of Participant Compliance with Study 
Intervention/Investigational Product  ................................ .............................. 50 
 Laboratory Evaluations  ................................ ................................ ............................... 50 
7.2.1  Clinical Laboratory Evaluations  ................................ ................................ ....50 
 Laboratory Specimen Preparation, Handling, and Storage  ............... 51 
 Laboratory Specimen Shippi[INVESTIGATOR_007]  ................................ ........................ 52 
 ASSESSMENT OF SAFETY  ................................ ................................ ............................... 53 
 Assessing and Recording Safety Parameters  ................................ .............................. 53 
8.1.1  Adverse Events (AEs)  ................................ ................................ .................... 53 
 Adverse Events Grading  ................................ ................................ ...53 
8.1.2  Serious Adverse Events (SAEs)  ................................ ................................ .....55 
 Specification of Safety Parameters  ................................ ................................ ............. 55 
 Reporting Procedures  ................................ ................................ ................................ ..56 
8.3.1  Reporting Serious Adverse Events  ................................ ................................ 56 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873227] Values or 
Abnormal Clinic al Findings ................................ ................................ ...................... 58 
 Halting Rules  ................................ ................................ ................................ .............. 58 
 Safety Oversight (ISM plus DSMB) ................................ ................................ ........... 59 
8.7.1  Independent Safety Monitor (ISM)  ................................ ................................ [ADDRESS_873228] (DSMB)  ................................ ................. [ADDRESS_873229]  ................................ ................................ ......................... 61 
 Informed Consent Process  ................................ ................................ .......................... 62 
 Consent for Future Use of Stored Specimens and Data  ................................ ............. 64 
 Exclusion of Women, Minorities, and Children (Special Populations)  ...................... 65 
 Participant Confidentiality  ................................ ................................ .......................... 65 
 Certificate of Confidentiality  ................................ ................................ ...................... 66 
 Costs, Participant Compensation, and Research Related Injuries  .............................. 67 
 STATISTICAL CONSIDERATIONS  ................................ ................................ ................. 68 
 Study Hypotheses  ................................ ................................ ................................ .......68 
 Sample Size Considerations  ................................ ................................ ....................... 68 
 Treatment Assignment Procedures  ................................ ................................ ............. 68 
10.3.1  Randomization Procedures  ................................ ................................ ............ 68 
10.3.2  Masking Procedures  ................................ ................................ ....................... 69 
 Planned Interim Analyses  ................................ ................................ ........................... 69 
10.4.1 Interim Safety Review  ................................ ................................ ................... 69 
10.4.2  Interim Efficacy Review  ................................ ................................ ................ 69 
 Final Analysis Plan  ................................ ................................ ................................ .....70 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  10 
CONFIDENTIAL  
 10.5.1  Analysis Populations  ................................ ................................ ...................... 70 
10.5.2  Baseline Characteristics  ................................ ................................ ................. 70 
10.5.3  Safety Analysis Plan  ................................ ................................ ...................... 71 
10.5.4  Efficacy Analysis Plan  ................................ ................................ ................... 71 
 Primary Efficacy Analysis  ................................ ................................ 71 
 Secondary Efficacy Analyses  ................................ ........................... 72 
 Exploratory and Other Efficacy Analyses  ................................ ........ 72 
 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  .............. [ADDRESS_873230] KEEPI[INVESTIGATOR_1645]  ................................ ................................ 76 
 Data Management Responsibilities  ................................ ................................ ............ 76 
 Data Coordinating Center/Biostatistician Responsibilities  ................................ ........ 76 
 Data Capture Methods  ................................ ................................ ................................ 76 
 Types of Data  ................................ ................................ ................................ .............. 77 
 Study Records Retention  ................................ ................................ ............................ 77 
 CLINICAL MONITORING  ................................ ................................ ................................ .78 
 PUBLICATION POLICY  ................................ ................................ ................................ ....79 
 LITERATURE REFERENCES  ................................ ................................ ............................ 80 
 APPENDICES  ................................ ................................ ................................ ...................... 81 
 Schedule of Events ................................ ................................ ............ 82 
 Toxicity Grading Table  ................................ ................................ .....86 
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873231] OF TABLES  
Table 17 -1: Schedule of Events  ................................ ................................ ................................ .....82 
Table 17 -2: Toxicity Grading Table  ................................ ................................ .............................. 86 
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873232] OF FIGURES  
Figure  1:  Schematic of Study Design  ................................ ................................ ........................ 19 
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873233] OF ABBREVIATIONS  
AE Adverse Event/Adverse Experience  
ASCUS  Atypi[INVESTIGATOR_651086]  
C. trachomatis  Chlamydia trachomatis  
DCF  Data Collection Form  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, 
NIH, DHHS  
DSMB  Data and Safety Monitoring Board  
eCRF  Electronic Case Report Form  
EIC Enrollment Informed Consent  
FDA  Food and Drug Administration  
FWA  Federal  Wide Assurance  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  14 
CONFIDENTIAL  
 GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HIV Human Immunodeficiency Virus  
HPF High -power field  
HPV  Human Papi[INVESTIGATOR_651087]’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IEC Independent or Institutional Ethics Committee  
IND Investigational New Drug Application  
IP Investigational Product  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ITT Intent -to-Treat  
KOH  Potassium Hydroxide  
LDPE  Low-Density Polyethylene  
MedDRA Medical Dictionary for Regulatory Activities  
mITT  Modified Intent -to-Treat  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_425553] s) 
NAAT Nucleic Acid Amplification Test  
N. gonorrhoeae  Neisseria gonorrhoeae  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  15 
CONFIDENTIAL  
 NIAID  National Institute of Allergy and Infectious Diseases, NIH, 
DHHS  
NIH National Institutes of Health  
OER  Office of Extramural Research  
OHRP  Office for Human Research Protections  
PCR  Polymerase Chain Reaction  
PD Protocol Deviation  
PI [INVESTIGATOR_651088]-Protocol  
PPROM  Preterm Premature Rupture of Membranes  
PVC  Polyvinyl Chloride  
QA Quality Assurance  
QC Quality Control  
SAE  Serious Adverse Event/Serious Adverse Experience  
SAP Statistical Analysis Plan  
SDCC  Statistical and Data Coordinating Center  
SIC Screening Informed Consent  
SOP Standard Operating Procedure  
STI Sexually Transmitted Infection  
SubI  Sub Investigator  
TEAE  Treatment -Emergent Adverse Event  
TOC  Test of Cure  
T. vaginalis  Trichomonas vaginalis  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873234]/Final Follow -up, weeks 9 -12 
 
 
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  17 
CONFIDENTIAL  
 PROTOCOL SUMMARY  
 
Title:  A Randomized, Double -Blind, Placebo -Controlled Trial of TOL -
463 Insert for Suppression of Bacterial Vaginosis (BV)  
Design of the Study:  
 TOL -[ADDRESS_873235] enrollment  (V1)  at Visit 2 (Day 29 ), Visit 3 (Day 
57) and Visit  4 /TOC (Day 85 ) for safety, clinical, and laboratory 
assessment.  
Study Phase:  II 
Study Population:  Approximately  [ADDRESS_873236] three  diagnoses  of BV in the prior 12 months, including the 
diagnosis at the initial screening visit to enroll approximately 
250 participants (to achieve 200 evaluable participants).   
Number of Sites:  Four  (Birmingham, Alabama; Pi[INVESTIGATOR_9109], Pennsylvania ; 
Chicago, Illino is; San Diego, [LOCATION_004] ) 
Description of Study 
Product : TOL -463 Insert or placebo admi nistered  vaginally twice -weekly 
for 12 weeks  
Study Objectives : 
 Primary:  
• To evaluate the clinical efficacy of a twice -weekly 
application of TOL -463 vaginal insert in suppression of BV 
in women with a history of recurrent BV (RBV)  following 
successful induction with oral metronidazole  or a CDC -
recommended  BV treatment  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  18 
CONFIDENTIAL  
 Secondary:  
• To evaluate t he time to BV recurrence  as defined by [CONTACT_589763]  
• To evaluate the incidence of vaginal symptoms over study 
participation   
• To evaluate acceptability of a twice -weekly application of 
TOL -463 vaginal insert in suppression of BV  
• To evaluate the safety of TOL -463 vaginal insert compared 
to placebo , including the incidence of secondary VVC  
Exploratory : 
• To evaluate the performance of the BD Max Vaginal Panel in 
characterizing  clinical and microbiologic outcomes of the 
intervention  
Duration of Individual 
Participant  Participation:  Participation will include a Screening Visit, an Enrollment Visit, 
and [ADDRESS_873237] 
Participant /Last Study Day:  Approximately 24 months.   
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  19 
CONFIDENTIAL  
 Figure  1:  Schematic of Study Design  
 
 
 
 
 
Randomize (1:1)  
125 subjects 
TOL -463 
Insert  
125 subjects 
Placebo  
Total 600: Screening:  Obtain Screening informed consent; perform screening; collect history, 
conduct clinical assessments and pregnan cy test.  
Study Visit 0:  
Screening  
(Day -15 to -8) 
 
Study Visit 1:   
 Enrollment (Day 1)  BV infection -Treat with 
Metronidazole or a CDC -
recommended BV treatment  
BV cleared ? 
Dispense IP and issue participant memory aid  Amsel positive for 
BV ( >2) and/or BV 
symptoms  Amsel negative for 
BV (≤2) and 
Asymptomatic  
End of study 
participation  Enrollment: Obtain Enrollment informed 
consent  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873238] clinical evaluations; assess AEs; collect IP containers ; review 
memory aid ; complete satisfaction questionnaire  
 Conduct clinical evaluations; assess AEs; collect  IP containers/dispense 
IP; review memory aid – participants with >2 Amsel criteria  will be 
terminated (complete satisfaction questionnaire)  
 
 
 Conduct clinical evaluations; assess AEs; collect IP containers/dispense 
IP; review memory aid  – participants with >2 Amsel criteria will be 
terminated (complete satisfaction questionnaire)  
 Study Visit 2:  
Follow -up 
(Day 29-35) 
Study Visit 3:  
Follow -up 
(Day 57 -63) 
Study Visit 4:  
Follow -up/TOC 
(Day 85 -91) 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  21 
CONFIDENTIAL  
 
 KEY ROLES  
Lead Principal 
Investigator:  
 
[INVESTIGATOR_71445]:   
Jeanne Marrazzo, MD, MPH  
University of Alabama at Birmingham School of Medicine  
Tinsley Harrison Tower [ADDRESS_873239].  
Birmingham, AL [ZIP_CODE] -0006  
 
 
Jonathan Glock, MPH  
DMID/NIAID/NIH  
[ADDRESS_873240], 8E48  
Rockville, MD [ZIP_CODE]  
 
  
Statistical and Data 
Coordinating Center  
(SDCC) : 
 The Emmes  Company, LLC  
[ADDRESS_873241]. Suite 700  
Rockville, MD [ZIP_CODE]  
(301) 251 -1161  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  22 
CONFIDENTIAL  
 
 BACKGROUND AND SCIENTIFIC RATIONALE  
 Background  
Bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) , collectively referred to as 
vaginitis,  are the two most prevalent lower reproductive tract infections, affecting tens of 
millions of women  annually in the [LOCATION_002]  (US)  and far more globally.  BV is 
characterized by a general depletion of specific Lactobacillus species that are necessary for 
maintain ing vaginal health and a dramatic increase in commensal organisms, notably 
Gardnerella vaginalis  and other anaerobes; a local inflammatory response to Candida  species 
(primarily C. albicans ) characterizes VVC . Although currently recommended reg imens afford 
reliable symptom relief, failure rates for BV and VVC are as high as 83% and 60%, respectively,  
[1-3] and in which the survival of resistant biofilm communities have been increasingly 
implicated.  These failure rates represent an important public health concern because these 
infections ar e associated with a host of serious complications including increased risk of 
acquiring and transmitting human immunodeficiency virus (HIV) and other sexually transmitted 
infections (STIs) and adverse pregnancy outcomes, including preterm premature rupture  of 
membranes (PPROM), preterm birth and low birth weight infants .[4-6] 
This study will assess the efficacy of TOL -[ADDRESS_873242] commonly diagnosed cause of this syndrome  across all care settings, 
including prenatal clinics, primary care clinics, and women’s health settings .[4, 7] Well -executed 
studies  indicate that up to one -third of adult women in the US may have BV at any given 
time, [8] and the population attributable risk in the US of BV for pre -term (early) deliveries, 
which are associated with substantial infant and maternal morbidity, has been estimated to be as 
high as 30%. [7] This is likely mediated by [CONTACT_651119][INVESTIGATOR_651089] -amniotic infection and subsequently PPROM 
and preterm delivery. Moreover, it is well establis hed that BV increases women’s risk of upper 
reproductive tract infection (pelvic inflammatory disease  (PID)) and of acquiring and 
transmitting other genital infections, notably HIV, human papi[INVESTIGATOR_28597] (HPV), and genital 
herpes. [4] Unfortunately, current treatment o ptions are limited to nitroimidazole  and 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873243] scientific consensus recognizing the serious 
adverse outcomes associated with BV, these treatment options are suboptimal. While some 
women derive immediate relief fr om the available antibiotic -based therapi[INVESTIGATOR_014], therapeutic cure 
rates remain low; moreover, recurrence after initially successful treatment is the rule. Over 70% 
of women in prospective studies experience recurrence in the year following treatment, often 
multiple times. [4, 9] New and innovative approaches for the immediate t reatment and ongoing 
suppression for BV are urgently needed, especially ones that can address the exceedingly 
common problem of BV persistence and recurrence.  
2.2.[ADDRESS_873244] course 
oral metronidazole  or a CDC -recommended  BV treatment .  Participants will be randomized to 
receive either TOL -463 Insert or placebo.   
2.2.3 Study Population  
Women between the ages of 18 and 55 presenting to US health clinics and responding to 
advertisements will be invited to participate in this study.  Women who are pregnant will not be 
permitted to enroll as TOL -463 Insert has not been studied in pregnancy.   
 Potential Risks and Benefits  
2.3.1 Pote ntial Risks  
There may be  some physical discomfort associated with pelvic examination and with obtaining 
vaginal secretions for microscopy and diagnostic tests. If a Pap smear is needed it may cause 
minor crampi[INVESTIGATOR_651090].  Informatio n concerning participants’ sexual 
history is necessarily detailed given the study’s objectives and may provoke some minor 
psychological or emotional stress when requested; women who receive a new diagnosis of a STI 
during the study may also experience mino r psychological or emotional stress. The oral 
metronidazole that eligible screened participants will take is recommended by [CONTACT_651120].  If a different 
regimen recommended  for the treatment of BV by [CONTACT_651121], refer to the packaging insert 
for the potential side effects.  Participants who develop VVC during study participation and use 
oral fluconazole may experience possible side effects as describe d in the packaging insert.   It is 
possible that a participant’s  cleared BV may not be suppressed by [CONTACT_651122] -[ADDRESS_873245] to the participant . 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  24 
CONFIDENTIAL  
  
 Potential Risks Associated with T OL-463 
The safety and tolerability of TOL -463 are supported by [CONTACT_651123] I and 
Phase II clinical studies  sponsored by [CONTACT_651124], Division of Microbiology and 
Infectious Diseases (DMID Protocol No. 11 -0077  and 15 -0039, r espectively ). The findings are 
consistent with the two -week Good Laboratory Practice (GLP) vaginal irritation and toxicity 
study of TOL -[ADDRESS_873246] 
common treatment -related adverse event s, (AEs),  reported in TOL -[ADDRESS_873247] . All treatmen t-related AEs were mild to moderate in intensity and self -limiting . No 
serious or severe AEs related to TOL -463 we re reported.  Please  refer to Investigator’s Brochure  
(IB) for additional information.  
2.3.[ADDRESS_873248] is recognized as an effective component of 
multi -drug regimens to prevent recurr ent BV .[10-12] Thus, women may benefit from  the use of a 
novel agent that incorporates this chemical compound into therapeutic form for th ese infection s.    
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873249] of cure (TOC) visit . The study is designed to determine the 
clinical efficacy of  an investigational product  (IP), TOL -[ADDRESS_873250] baseline clinical information collected at Visit 0, 
screening (Day -15 to -8), (V0) . This information will consist of demographics, current vaginal 
symptoms, medical and sexual history, concomitant medications, and clinical and laboratory 
finding s. Participants will undergo a pelvic examination  and have vaginal specimens collected 
for confirmation of BV and for diagnostic testing for common STIs (C. trachomatis , N. 
gonorrhoeae , and T. vaginalis ). Women with a clinical diagnosis of BV who meet all other 
screening Inclusion/Exclusion criteria  will be treated with oral metronidazole, 500 mg twice a 
day for 7 days, or another CDC -recommended  BV treatment, and scheduled for a  Visit 1, 
enrollment , (V1)  in [ADDRESS_873251] negative for BV, 
defined as ≤ 2 of 4  Amsel criteria  and absence of symptoms of BV (absence of homogenous 
discharge and odor) , will be offered to review and sign the Enrollment consent.  Women who 
consent and qualify will be enrolled and randomized  (1:1)  to one of two groups (TOL -463 Insert 
or placebo).  IP will be administered vaginally, twice -weekly for 12 weeks . Follow -up clinic 
visits will occur at Visit 2 ( V2), Visit 3 ( V3), and Visit 4 ( V4).  For women with cleared BV at 
enrollme nt, the primary endpoint will be clinical failure, RBV occurring by V4.   
Safety will be measured by [CONTACT_163400], targeted physical examination, and pelvic 
examination. All AEs will be collected through V 4. Safety oversight will be provided by a Dat a 
and Safety Monitoring Board (DSMB).  
Laboratory testing will include urine pregnancy, nucleic acid amplification tests (NAATs) for 
chlamydia, gonorrhea, and trichomoniasis, and Gram stain for Nugent scoring, as well as 
assessment of vaginal pH, saline mic roscopy (clue cells, motile trichomonads, ye ast forms), and 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  26 
CONFIDENTIAL  
 KOH preparation at each site’s local lab.  Candi da culture will be performed as clinically 
indicated. Polymerase Chain Reaction, PCR -based molecular diagnosis of BV through a multi -
organism PCR algorithm on the BD Max Vaginal Panel will be performed at a certified 
laboratory for all  scheduled study visits .   
The duration of the study for participant s who are enrolled and randomized  will be 
approximately 100 days. For those not enrolled, participation will end at their  V1, Day 1.   
Enrollment is expected to be completed in  approximately  twenty four months.  
All participants will be asked to abstain from anal, receptive oral, and vagina l sexual intercourse 
within one hour of IP administrat ion and for 24 hours after . Participants who are  sexually active  
will be required  to use an effective form of birth control during study participation through  the 
final visit /V4. A simplified participant memory aid will be provided to study participants to 
document symptom s, AEs, and protocol compliance.   
For additional details on study procedures and evaluations and study schedule by [CONTACT_319650], see 
Sections 6 and 7 and Appendix A  
 Study Objectives  
3.2.1 Primary   
• To evaluate the clinical efficacy of a twice -weekly application of TOL -463 vaginal insert in 
suppression of BV in women with a history of recurrent BV (RBV) following successful 
induction with oral metronidazole  or another CDC -recommended  BV treatment . 
3.2.2 Secondary  
• To evaluate the time to BV recur rence  as defined by [CONTACT_316316] . 
• To evaluate the incidence of vaginal symptoms over study participation . 
• To evaluate acceptability of a twice -weekly application of TOL -463 vaginal insert in 
suppression of BV.  
• To evaluate the safety of TOL -463 vagina l insert compared to placebo, including the 
incidence of secondary VVC . 
3.2.3 Exploratory   
• To evaluate the performance of the BD Max Vaginal Panel in characterizing  clinical and 
microbiologic outcomes of the intervention . 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  27 
CONFIDENTIAL  
 
 Study Endpoints  
3.3.1 Primary Endpoint  
• Among participants with RBV at baseline, the proportion of participants with recurrent BV 
by V4 as defined by [CONTACT_651125] [Study day 8 5-91]. 
Recurrence of BV at each follow -up visit is defined as > 2  of the following Amsel criteria:  
a. Positive KOH  whiff test  
b. Homogeneous discharge characteristic of BV  
c. Clue cells ≥ 20% of vaginal squamous epi[INVESTIGATOR_1663]  
d. Vaginal pH >  4.[ADDRESS_873252] -related following initiation of study treatment 
and through the final study visit . 
5. The occurrence of culture confirmed secondary VVC following initiation of study 
treatment and through the final study visit .  
3.3.3 Exploratory  Endpoint   
• To evaluate the performance of the BD Max Vaginal Panel in characterizing clinical and 
microbiologic outcome s of the intervention . 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  28 
CONFIDENTIAL  
 
 STUDY INTERVENTION /INVESTIGATIONAL 
PRODUCT  
Oral metronidazole , 500mg,  is acquired locally at each site and provided  to participants  as 
standard of care  for women  with BV  who are eligible  during the Screening Visit, V0.  Store per 
manufacturer’s instructions.  If another CDC -recommended  BV treatment is provided to 
participants , it would be acquired locally at each site and stored per manufacturer’s instructions.   
Oral fluconazole is acquired locally at each site and provided to participants as standard of care 
for women with VVC infections.  Store per manufacturer’s instruction s.  
 Study Product Description   
TOL -[ADDRESS_873253] is formulated as a hydrophilic melt insert. All excipi[INVESTIGATOR_651091] (USP -NF) materials and are 
formulated at levels consistent with the acceptable use ranges specified within the FDA Inactive 
Ingredient Guide.  
4.1.1 Formulation, Packaging, and Labeling  
TOL -463 Vaginal Inserts  and Placebo  
TOL -463 vaginal inserts and matching Placebo vaginal inserts will be supplied in 2.0 cc/g low -
density polyethylene (LDPE) + polyvinyl chloride (PVC) plastic unit -dose insert molds with ten 
vaginal applicators .  
All study product will be labeled according t o manufacturer or regulatory specifications and 
include the statement “Caution:  New Drug – Limited by [CONTACT_336820].”   
Clinical trial material (CTM) will be double blinded  and ongoing stability studies conducted on 
those CTM lots to s upport the conduct of the clinical trial.  
Please see IB for additional information.  
4.1.[ADDRESS_873254] Storage and Stability  
TOL -463 Vaginal Inserts  
The TOL -463 inserts should be stored at room temperature (20 -25°C/68 -77°F)  and are expected 
to be stable for at least 24 months under these conditions based on stability data for TOL -463 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873255] integrity under the specified storage conditions.  
 
Placebo  for Vaginal Inserts  
Placebo inserts  should also be stored at room temperature (20 -25°C/68 -77°F) .  Stability testing 
of the placebo insert  lot manufactu red for this study will remain ongoing throughout the course 
of the trial to ensure product integrity under the specified storage conditions.  
 Acquisition/Distribution  
TOL -[ADDRESS_873256] by [CONTACT_122830], the investigational products will be trans ferred to the following address:  
DMID Clinical Materials Services (CMS)  
Fisher BioServices  
[ADDRESS_873257]  
Germantown, MD [ZIP_CODE]  
Phone: (240) 477 -1350  
Fax: (240) 477 -1360  
Email: DMID. CMS @ThermoFisher.com  
Study products will be shipped from the  DMID Clinical Materials Services (CMS)  to the 
investigational site upon request and approval by [CONTACT_651126].  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  30 
CONFIDENTIAL  
 
 Dosage, Preparation , Dispensing  and Administration of Study 
Intervention/Investigational Product  
The Research Pharmacist or delegated study staff is responsible for ensuring that the policies and 
regulations within their jurisdiction are followed when preparing and dispensing study products. 
This includes following requirements as they pertain to prescriptions, medication prescribing 
orders and label ing. In addition, instructions specific to a trial or about a study product must also 
be followed. A Site Research Pharmacist may be delegated the responsibility of IP dispensation. 
The Research  Pharmacist must be a licensed, registered pharmacist and is t he preferred 
healthcare practitioner to be delegated to perform this activity. If a Research Pharmacist is not 
available, a physician, nurse practitioner, physician assistant, registered nurse, or other 
authorized healthcare practitioner who is a member of  the clinical study staff may be delegated 
to dispense the IP. These personnel must be licensed, trained, and qualified to prepare 
investigational study product and must be authorized to dispense the IP under state and local 
rules and regulations.   
Partic ipants will be randomized to one of two IPs, as follows:  
• TOL -463 Vaginal Insert: Administered vaginally as a single 2 g unit dose twice a week with 
a minimum of a two-day duration in between doses for twelve weeks  with the aid of a 
disposable applicator . 
• Placebo :  Administered vaginally as a single 2 g unit dose twice a week with a minimum of a 
two-day duration in between doses for twelve weeks with the aid of a disposable applicator.  
 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
Fisher will ship packaged IP to the in vestigational sites.  At each site , the IP will be stored 
appropriately, including segregation in a secure location and under controlled storage conditio n 
and in accordance with applicable regulatory requirements  and administered by [CONTACT_651127].  A drug accountability log will be filled out for all IP at the sites.   
After receipt of the IP, the site PI [INVESTIGATOR_651092]. The site PI [INVESTIGATOR_421220] a site research 
pharmacist or an appropriately qualified staff member the responsibility for IP accountability. 
The designee will be responsible for maintai ning complete records and documentation of product 
receipt, accountability, dispensation, temperature and storage conditions, and final disposition of 
IP. All IP, whether administered or not, must be documented on the appropriate IP accountability 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873258] o r dispensing log. The sponsor's monitoring staff will verify the participating clinical 
sites’ IP accountability records and dispensing logs per the study monitoring plan.  
Used and unused IP will be retained until monitored and released for disposition, as applicable. 
This can occur on an ongoing basis for used IP. 
Used IP and its packaging may be destroyed in accordance with site -specific SOPs following 
each monitoring visit where IP account ability is monitored, and discrepancies  resolved .  
However, retaining used  IP and/or  its packaging  until a monitoring visit occurs is only required 
when the local institution’s SOP mandates.  If local SOPs allow destruction of IP  and its 
packaging , both can be destroyed per the site’s SOPs prior to monitoring visits  and after written 
permission is given by [CONTACT_122830] .  The site will ensure a double count of the IP  and the packaging  is 
performed and documented before destruction for use in monitor reconciliation .  Further 
instructions are described in the protocol -specific MOP.  
Unused dispensed IP and its packaging returned (from study participants) to the site will be 
accounted for at the site and participant compliance will be recorded.  Any unused  returned  IP 
and its packaging  will be disposed in accordance with site -specific SOPs .  
Upon completion or termination of the study and after the final mo nitoring visit  where IP 
accountability is monitored, and resolution of any discrepancies, final disposition of the unused  
(never dispensed  IP) will be disposed in accordance with the Manual of Procedures ( MOP ) and 
site-specific SOPs . 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873259] course of oral metronidazole  or another CDC -recommended  BV treatment .  Participants 
will return within approximately one week of completing the metronidazole treatment  or other 
CDC -recommended  BV treatment,  for assessment of clinical cure.  Clinical cure of BV is 
defined as ≤ 2 of 4 Amsel criteria and absence of reported symptoms of BV (i.e. no malodorous 
discharge consistent with BV).   
Participants who return for the Enrollment Vi sit, V1 and are determined to be clinically cured 
will be offered to review and sign the Enrollment consent.  Participants who consent and meet 
Enrollment eligibility will be randomized in a 1:1 ratio to twice weekly blinded suppressive 
therapy with TOL -463 or placebo.  It is estimated that approximately 250 participants will be 
eligible for Enrollment with approximately 125 participants in each suppressive therapy group.   
No exemptions will be granted on Screening or Enrollment eligibility criteria for th is DMID -
sponsored trial.   
Participants will be recruited from health clinics in the U.S.  
Those participants who enroll in the study will undergo up to 3 scheduled Follow -up visits to 
evaluate clinical diagnosis of BV at each visit.  Participants who devel op vaginal symptoms 
between scheduled visits will be asked to return for an unscheduled visit.  If at any time during a 
follow -up visit a participant is diagnosed with clinical BV (> 2 Amsel criteria), the study 
endpoint of BV reoccurrence is met, and participation  in the study  will end.    
The study will target a total of [ADDRESS_873260] meet all of the  following  inclusion criteria  to be eligible for inclusion in the study .  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  33 
CONFIDENTIAL  
 
 Screen ing Visit(s) Inclusion Criteria:  
1. Women with a current BV infection and a history of at least two previous epi[INVESTIGATOR_651093] -report  in the past year . V0 diagnosis is based on the presence of  
≥ 3Amsel criteria* ; 
*Homogeneous vaginal discharge;  positive KOH whiff test ; vaginal pH of > 4.5 ; and ≥ 
20% clue cells .   
2. Willing and able to p rovide written informed consent;  
3. Age 18-55 years of age  at the time of V 0; 
4. General good health based on medical history, targeted physical examina tion, and pelvic 
examination ; 
5. For participants [ADDRESS_873261] recent r esult being normal or ASCUS HPV negative  OR Pap smear collected at 
V0*; 
*Consistent with current Pap screening guidel ines, a Pap smear must be performed at V0, 
for women  who meet the following criteria and cannot provide documentation or self-
report of a normal or ASCUS HPV negative Pap smear , conducted within the prior 3 
years: (a) has not had a hysterectomy or (b) has had a hysterectomy and has a history of 
cervical intraepi[INVESTIGATOR_651094] 2+ (CIN2+) in the past 20 years.   
Note:   If a Pap smear is conducted at V 0, the results are not required prior to enrollment.  
6. Have a negative urine pregnancy test at V0, if of childbearing potential ; 
7. Must be of non -childbearing potential * OR must be using an effective method of birth 
control ** and must be willing to continue the method through the end of IP 
administration.   
*Defi ned as post -menopausal , or status post bilateral tubal ligation , or status post bilateral 
oophorectomy or status post hysterectomy.  
**Acceptable methods are defined as:  
a. IUDs  or hormonal contraceptives  for at least 22 days prior to screening .  Note:  
Intrav aginal contraceptive rings (e.g., NuvaRing) are not acceptable forms of birth 
control for this study.  
b. Consistent use of a barrier method, including diaphragms or condoms, for at least 
[ADDRESS_873262] 13 days prior to screening .  
d. Exclusively same -sex relationship.  
e. Monogamous relationship with vasectomized partner.   
8. Willing and able to cooperate to the extent and degree required by [CONTACT_651128].  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  34 
CONFIDENTIAL  
 
 Enrollment Visit Inclusion Criteria:  
In addition to confirming all  relevant  Screening Visit Inclusion Criteria, women  must meet 
all of the following criteria to be elig ible for enrollment in the study.  
1. Willing and able to p rovide Enrollment w ritten informe d consent;  
2. After completion of metronidazole induction therapy  or another CDC -recommended  BV 
treatment , no clinical evidence of BV * and absence of symptoms of BV ** at V1;  
*As defined by ≤ 2 of 4 Amsel criteria.  
**Defined as absence of  vaginal discharge and odor  consistent with BV .   
3. Must have a negative urine pregnancy test at  V1, if of childbearing potential ; 
4. Willing to refrain from any intravaginal products/medications* other than the IP 
throughout the course of the trial ; 
* For example: douches, antifungal or antibacterial preparations, lubricants, contraceptive 
creams, gels, foams, sponges , spermicides . 
5. Must agree to abstain from receptive oral, anal, and vaginal sexual intercourse one hour 
prior to  IP administration and fo r 24 hours after ; 
6. Willing to refrain from using tampons or menstrual cups for [ADDRESS_873263] be of non -childbearing potential* OR must be using an effective method of birth 
control** and must be willing to continue the method throug h the end of IP 
administration.   
*Defined as post -menopausal , or status post bilateral tubal ligation , or status post bilateral 
oophorectomy or status post hysterectomy.  
**Acceptable methods are defined as:  
a. IUDs or hormonal contraceptives for at least 30 days prior to using IP .  Note:  
Intravaginal contraceptive rings (e.g., NuvaRing) are not acceptable forms of birth 
control for this study.  
b. Consistent use of a barrier method, including diaphragms or condoms, for at least 
[ADDRESS_873264] 21 days prior to using IP.  
d. Exclusively same -sex relationship.  
e. Monogamous relationship with vasectomized partner.  
 
5.1.2 Participant  Exclusion Criteria  
Women who  meet any of the following exclusion crit eria will be excluded from the study . 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  35 
CONFIDENTIAL  
 
 Screening Visit(s) Exclusion Criteria : 
1. Diagnosis  of another vaginal or vulvar condition  that may  confuse interpretation of 
response to IP*;  
*For example: erosive lichen planus, desquamative inflammatory vaginitis, or contact 
[CONTACT_651129] v ulvar epi[INVESTIGATOR_2130] .   
2. Concurrent VVC infection with inability to be treated with oral fluconazole ;  
3. Infectious cause of cervicitis (e.g., N. gonorrhoeae , C. trachomatis , or T. vaginalis ) 
confirmed on physical examination and/or  with laboratory testing **+;    
** Women may be rescreened  for eligibility following successful treatment of 
confounding STI .  
+Results of NAAT testing will be reviewed prior to e nrollment.  
4. Active genital lesions, including ul cers or vesicles consistent with herpes or warts;  
5. Planned ongoing immunosuppressive therapy or systemic antibiotic treatment during the 
course of the study;  
6. History of h ypersensitivity , allergy or other contraindication(s) to metronidazole or other 
CDC -recommended  BV treatment  used to treat subject ; 
7. History of hypersensitivity to any TOL -463 formulation components  (see I B for product  
information ); 
8. Current or untreated c ervical  intraepi[INVESTIGATOR_28601] (CIN) or cervical carcino ma; 
9. Currently pregnant or nursing;  
10. Any other condition that, in the opi[INVESTIGATOR_871], would interfere with 
participation in the study ; 
11. Previous enrollment in the study  or at the investigator’s discretion . 
 Enrollment Visit Exclusion Criteria:  
In addition to confirming all Screening Visit Exclusion  Criteria, women  who meet any of the 
following criteria will not be eligible for enrollment  in the study.    
1. Active menses or significant vaginal bleeding as determined by [CONTACT_651130] 
V1*; 
* Note: women who are menstruating may be reevaluated for study enrollment within the 
enrollment window . 
2. Use of vaginal or systemic antibiotic  or antifungal since V0, other than oral 
metronidazole , CDC -recommended  BV treatment,  or oral fluconazole,  as per protocol ; 
3. Evidence or suspi[INVESTIGATOR_651095] V1 ;  
4. Concurrent  VVC infection at V1 with inability to treat with o ral fluconazole;   
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  36 
CONFIDENTIAL  
 5. Use of any investigational drug within 30 days prior to V1 or planned/anticipated  use 
during  study participation . 
 Withdrawal from the Study, Discontinuation of Study Product, or 
Study Termination  
5.2.[ADDRESS_873265]  
 Reasons for Study Withdrawal  
Participants  may voluntarily withdraw their consent for further study participation at any time 
and for any reason  without penalty or prejudice to future medical care.    
Participants may be required to withdraw from fur ther study  participation after discussion with 
the investigator for the following reasons:   
• AE(s) judged to be severe (Grade 3) and related to IP 
• SAE(s) judged to be related to IP 
• Diagnosis of VVC at any follow -up visits, V 2 or V3, or unscheduled  visit(s)  and cannot 
be treated with oral fluconazole  
• A Pap test result from V0  that was anything other than normal or ASCUS HPV negative ; 
participant is no longer eligible for the study.   
• Medical disease or condition, or new clinical finding(s) for which continued  
participation, in the opi[INVESTIGATOR_651096], interfere with the participant’s successfully completion of the study, or 
interfere with the evaluation of responses  
• Violation of  eligibility criteria  
• Signif icant deviation from the treatment plan specified in the protocol  (i.e., incorrect 
administration of IP, failure to attend study visits ) 
• Participant  lost to follow -up 
• At the discretion of the investigator  
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873266] be recorded in the case report forms (CRFs).   The investigator will inform the 
participant  that data that has already been collected will be retained and analyzed even if the 
participant  withdraws from this study.   
If withdrawal occurs after enrollment , any participant with an ongoing AE will be followed until 
the AE is resolved or until the participant’s condition becomes stable.  
Participants who request to withdraw their consent from further study participation after study 
treatment with IP , will be reminded of the importance of continuing in t he study for safety 
evaluations and will be encouraged to complete the Early Termination Visit if they choose not to 
complete the remaining study visit (s).  The Early Termination Visit procedures are listed in 
Section 6.3.4 .  Participants who choose to decline continuation in study participation will no 
longer be contact[CONTACT_51095] -up. 
In the case of participants who fail to appear for a follow -up safety assessmen t, extensive effort 
(i.e., three documented contact [CONTACT_92238], emails, etc., made on separate 
occasions) will be made to locate or recall them or at least to determine their health status.  
Participants who cannot be located after extensive effort will no longer be contact[CONTACT_51095] -
up.  These efforts will be documented in the participant’s records.  
If a participant is withdrawn from the study due to an AE that prohibits continued participation in 
the study, she will be given appropriate c are and treatment under medical supervision until the 
condition has resolved or becomes stable.  
Safety and efficacy data will be collected on any participant who is withdrawn from the efficacy 
endpoint analysis.  Withdrawal of participants from the analysi s populations is discussed in 
Section 10.5.[ADDRESS_873267]  
A participant may discontinue use of the IP as a result of their own decision, due to  the 
investigator’s  discretion, or due to an AE.  All participants who discontinue use of the IP will be 
encouraged to complete the Early Termination Visit.  The Early Termination Visit procedures 
are listed in Section 6.3.4 .      
If the participant discontinued use of the IP due to an AE, she will be given appropriate care and 
treatment under medical supervision until the condition has resolved or becomes stable.  If the 
participant  consents, every attempt will be made to follow al l AEs through resolution.   
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  38 
CONFIDENTIAL  
 5.2.2 Participant  Replacement  
Participants  who sign the Enrollment Informed Consent ( EIC), are randomized and receive IP 
and then subsequently withdraw, or are withdrawn from this study, or are lost to follow -up will 
not be replaced.  Participants  who withdraw  consent after signing the EIC form and are 
randomized  but have not received  IP may be replaced.   
5.2.3 Study Termination  
Although the study sponsor has every inten tion of completing the study, the sponsor  reserves the 
right to termin ate the study at any time for clini cal or administrative reasons. Reasons for 
termination include, but are not limited to, study closure due to DSMB review and 
recommendation or  at the discretion of DMID . 
If the study is prematurely terminated for any reason, the investigator will promptly inform the 
study participants  and assure appropriate therapy or follow -up for the participants , as necessary. 
The investigator will provide a detailed written explanation  of the termination to the IRB/IEC.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  39 
CONFIDENTIAL  
 
 STUDY PROCEDURES  
Study visit information is listed in this section, Section  7, and the Schedule of Events ( Appendix 
A). Further instructions are described in the protocol -specific MOP.  
 Visit 0 (Day -15 to -8) Screening  
• Potential participants will be provided with a description of the study (purpose and study 
procedures) and asked to read and sign the Screening I nformed Consent form , (SIC) . The 
SIC will be signed prior to performing any study procedures, including any scr eening 
procedures.  
• Demographic information will be collected from the participant.  
• Eligibility criteria will be reviewed with the participant.  
At this juncture, if a potential participant is not eligible, information regarding reason for screen 
failure will be noted and the participant will not have any additional screening procedures 
completed . 
• Complete medical history will be obtained by  [CONTACT_651131] , if available, to assure eligibility.  
• Vaginal symptom s such as odor, itching, irr itation , and discharge  will be reviewed with the 
participant.  
• Sexual history for the past 30 days will be collected.  
• A urine pregnancy test will be performed on all participants of childbearing potential and 
must be negative pri or to administration of oral metronidazole  or other CDC -recommend  BV 
treatment induction therapy . 
• All concomitant medications taken in the last 30 days will be recorded on the appropriate 
data collection form  (DCF) . 
• A pelvic examination to include examinat ion of external genitalia will be conducted using a 
non-lubricated speculum and swabs and samples obtained for analysis of Amsel criteria; 
KOH and saline microscopy for identification of yeast forms , trichomonas, and clue cells ; 
NAAT for C. trachomatis, N.  gonorrhoeae , and T. vaginalis ; BD Max baseline test ; future 
analysis , for participants who consented to future use of their specimens ; and Gram staining 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  40 
CONFIDENTIAL  
 for Nugent scoring.  Instructions for obtaining vaginal swab specimens for these assessments 
are outlined in the protocol -specific MOP . Gram stain Nugent scoring will be conducted in 
the Central Laboratory; all other testing will be conducted locally. A Pa p smear should also 
be done for any participant who meets the following criteria and cannot provide 
documentation (which can include self -report) of a normal or ASCUS HPV negative Pap test 
within the prior 3 years: is 21 years of age or older and (a) has n ot had a hysterectomy or (b) 
has had a hysterectomy and has a history of CIN2+ in the past 20 years. If a Pap smear is 
conducted at V 0, the results are not required prior to enrollment.  
• Vulvovaginal signs such as erythema, edema, excoriation, and discharge  will be documented 
and graded by [CONTACT_926] , as applicable . 
• A clinical determination for BV  will be made based on evaluation of Amsel criteria; the 
presence of 3/4 criteria is required for a diagnosis of BV at this initial screening.  
• BV positive p articipan ts meeting all other study criteria will be provided with oral 
metronidazole, 500 mg twice daily for 7 days  or another CDC -recommended  BV treatment . 
• Participants will be scheduled to return for Visit 1 (Day 1) Enrollment  to assess response to 
metronidazole  or other CDC -recommended  BV treatment induction therapy and if 
determined to be a clinical BV cure  (by [CONTACT_651132])  and asymptomatic  will be invited to 
review and sign the EIC.  If participants are not able to keep the scheduled Visit [ADDRESS_873268] be re -screened before they can be enrolled.  
 Visit 1 (Day 1) Enrollment  
• Study personnel will review screening study eligibility criteria to ensure unchanged since the 
initial screening visit.  
• Vaginal symptoms such as odor, itching, irritation, and discharge will be reviewed with the 
participant.  
• Vulvovaginal signs such as erythema, edema, excoriation,  and discharge, will be documented 
and graded by [CONTACT_926] , as appl icable . 
• A pelvic examination to include examination of external genitalia will be conducted using a 
non-lubricated speculum and swabs and samples obtained for analysis of Amsel criteria ; 
KOH and saline microscopy for identification of yeast forms , trichomo nas, and clue cells .   
Instructions for obtaining vaginal swab specimens for these assessments are outlined in  the 
protocol specific MOP .  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  41 
CONFIDENTIAL  
 • A clinical determination to confirm BV cure, determined by ≤ [ADDRESS_873269] to the participant .  
• Participants who no longer have BV, will be asked to read and sign the EIC  at this time .  The 
EIC form  will be signed prior to performing any study procedures.  
• Enrollment eligibility criteria will be reviewed with the participant.  
• Medical history will be reviewed and updated as appropriate.  
• Interim sexual history since the last clinic visit will be collected.  
• A urine pregnancy test will be performed on all participants of childbearing potential and 
must be negative.  
• All concomitant medications taken since V 0 will be recorded on the appropriate DCF . 
Previously recorded medications will be updated as appropriate.  
• Participants will be registered in Advantage  eClinical after being classified as negative for 
BV and eligible for the study , and randomly assigned to active treatment (TOL -463 Insert) or 
placebo.  
• A target ed physical examination including height and weight  will be performed by a 
qualified study clinician.  
• Collect vaginal swabs fo r Gram staining for Nugent scoring; the BD Max test ; and for future 
analysis, for participants who consented to future use of their specimens . See the protocol -
specific MOP for guidance  on swab collection . 
• Participants with clinical evidence of VVC based on vulvovaginal signs (edema, erythema, 
and/or excoriation) and symptoms (vulvovaginal itching, burning, and/or irritation) will have 
a confirmatory vaginal Candida culture and treated as appropriate with oral fluconazole.   
Participants who cannot take oral fluconazole will be terminated from the study.  
• Blinded IP based on randomization assignment will be provided to the participant in a 
prepared kit with other study supplies.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  42 
CONFIDENTIAL  
 • Study protocol requirements and dosing instructions will be reviewed with the participant 
and a participant memory aid and written study instructions provided.   Participants will be 
counseled to refrain from receptive oral, anal, and vaginal sexu al intercourse [ADDRESS_873270] the accuracy of vaginal pH measurement .  
• Participants will be scheduled to return for follow -up at Visit 2 (Day 2 9). 
• Study staff will contact  [CONTACT_486477] a reminder for Visit 2 and to discuss adherence to IP 
and any barriers to IP use . 
 Planned Study Visits  
6.3.1 Visit 2 (Day 2 9 [Window:  Days 29-35]) Follow -up  
• Medical history will be reviewed and updated as appropriate.  
• Interim sexual history since the last clinic visit will be colle cted.  
• Vaginal symptoms will be assessed .  
• A urine pregnancy test will be performed on all participants of childbearing potential.  
• Compliance with the study protocol criteria will be assessed ; all used  and unu sed study IP 
packaging will be collected  as rele vant and recorded . 
• Participant memory aid will be collected and reviewed.    
• All concomitant medications taken since V 1 will be recorded on the appropriate DCF . 
Previously recorded medications will be updated as appropriate.  
• Study personnel will discuss with participants and assess and record all AE/SAEs. Previously 
recorded AE/SAEs will be updated as appropriate.  
• If clinically indicated, a  targeted physical examination will be performed by a qualified study 
clinician.  
• A pelvic examination to incl ude examination of external genitalia will be conducted,  and 
swabs and samples taken for analysis of Amsel criteria; KOH and saline microscopy for 
identification of yeast forms , trichomonas, and clue cells ; Gram staining ; the BD Max test; 
and for future analy sis, for participants who consented to future use of their specimens . 
Instructions for obtaining vaginal swab specimens for these assessments are outlined in  the 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  43 
CONFIDENTIAL  
 protocol specific MOP . Gram stain Nugent scoring will be  conducted in the Central 
Laboratory; all other testing will be conducted locally.  
• Participants with clinical evidence of VVC based on vulvovaginal signs (edema, erythema, 
and/or excoriation) and symptoms (vulvovaginal itching, burning, and/or irritation) will have 
a confirmatory vaginal Candida culture and treated as appropriate  with oral fluconazole.   
Participants who cannot take oral fluconazole will be terminated from the study.  
• Vulvovaginal  signs will be assessed  and graded by [CONTACT_926], as applicable .  
• A clinical determination for BV  recurrence  will be made based on evaluation of Amsel 
criteria . The presence of >2 of 4  Amsel criteria is required for a diagnosis of BV  recurrence .  
Participants  with a clinical diagnosis of BV recurrence will complete a satisfaction 
questionnaire and will be terminated from the study . 
• Participants who are negative for BV  recurrence  as determined by ≤ [ADDRESS_873271] the accuracy of v aginal pH measurement .   
• Study staff will contact [CONTACT_486477] a reminder for Visit 3 and to discuss adherence to IP 
and any barriers to IP use.  
6.3.2 Visit 3 (Day 5 7 [Window:  Days 57-63]) Follow -up 
• Medical history will be reviewed and updated as appropriate . 
• Interim sexual history since the last clinic visit will be collected.  
• Vaginal symptoms will be assessed.    
• A urine pregnancy test will be performed on all participants of childbearing potential.  
• Compliance with the study protocol criteria will be assess ed; all used  and unused  study IP 
packaging will be collected as relevant and recorded.  
• Participant memory aid will be collected and reviewed.  
• All concomitant medications taken since V 2 will be recorded on the appropriate DCF . 
Previously recorded medications will be updated as appropriate.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  44 
CONFIDENTIAL  
 • Study personnel will discuss with participants and assess and record all AE/SAEs. Previously 
recorded AE/SAEs will be updated as appropriate.  
• If clini cally indicated, a targeted physical examination will be performed by a qualified study 
clinician.  
• A pelvic examination to include examination of external genitalia will be conducted,  and 
swabs and samples taken for analysis of Amsel criteria; KOH and saline microscopy for 
identification of yeast forms, trichomonas, and clue cells ; Gram staining ; the BD Max test; 
and for future analysis , for participants who consented to future use of their specimens . 
Instructions for obtaining vaginal swab specimens for th ese assessments are outlined in the 
protocol specific MOP . Gram stain Nugent scoring will be conducted in the Central 
Laboratory; all other testing will be conducted locally.  
• Participants with clinical evidence of VVC based on vulvovaginal signs (edema, er ythema, 
and/or excoriation) and symptoms (vulvovaginal itching, burning, and/or irritation) will have 
a confirmatory vaginal Candida culture and treated as appropriate  with oral fluconazole .  
Participants who cannot take oral fluconazole will be terminated  from the study.  
• Vulvovaginal signs will be assessed and graded by [CONTACT_926], as applicable. A clinical 
determination for BV recurrence will be made based on evaluation of Amsel criteria .  The 
presence of  >2 of 4  Amsel  criteria is required for a diagnosis o f BV  recurrence .  Participants 
with a clinical diagnosis of BV recurrence will complete a satisfaction questionnaire and will 
be terminated from the study  
• Participants who are negative for BV recurrence determined as ≤ [ADDRESS_873272] the accuracy of vaginal pH measurement .   
• Study staff will contact  [CONTACT_486477] a reminder for Visit 4 and to discuss adherence to IP 
and any barriers to IP use.  
6.3.3 Visit 4 (Day 85  [Window:  Days 85-91]) Follow -up (TOC)  
• Medical history will be reviewed and updated as appropriate.  
• Interim sexual history since the last clinic visit will be collected.  
• Vaginal symptoms will be assessed.    
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  45 
CONFIDENTIAL  
 • A urine pregnancy test will be performed on all participants of childbearing p otential.  
• Compliance with the study protocol criteria will be assessed; all used and unused study IP 
packaging will be collected as relevant and recorded.  
• Participant memory aid will be collected and reviewed.  
• All concomitant medications taken since V 3 will be recorded on the appropriate DCF . 
Previously recorded medications will be updated as appropriate.  
• Study personnel will discuss with participants and assess and record all AE/SAEs. Previously 
recorded AE/SAEs will be updated as appropriate.  
• If clinic ally indicated, a targeted physical examination will be performed by a qualified study 
clinician.  
• A pelvic examination to include examination of external genitalia will be conducted,  and 
swabs and samples taken for analysis of Amsel criteria; KOH and salin e microscopy for 
identification of yeast forms, trichomonas, and clue cells ; Gram staining; BD Max  test; and 
for future analysis, for participants who consented to future use of their specimens . 
Instructions for obtaining vaginal swab specimens for these a ssessments are outlined in  the 
protocol specific MOP . Gram stain Nugent scoring will be conducted in the Central 
Laboratory; all other testing will be conducted locally.  
• Participants with clinical evidence of VVC based on vulvovaginal signs (edema, erythem a, 
and/or excoriation) and symptoms (vulvovaginal itching, burning, and/or irritation) will have 
a confirmatory vaginal Candida culture and treated .  
• Vulvovaginal signs will be assessed and graded by [CONTACT_926], as applicable. A clinical 
determination for BV  recurrence  will be made based on evaluation of Amsel criteria .  The 
presence of >2 of 4  Amsel criteria is required for a diagnosis of BV  recurrence . 
• Participant will complete a satisfaction questionnaire.  
6.3.4 Early Termination Visit   
The V4 assessments and DCF s (see Section  6.3.3 ) must be completed at the early termination 
visit for participants who withdraw, or are withdrawn, or terminated from the s tudy. If a 
participant withdraws between scheduled visits, the participant will be asked to return to  the 
clinic to perform the V4 assessments.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  46 
CONFIDENTIAL  
 
 Unscheduled Study Visits  
Unscheduled visits may occur at any time during the study. For example, for problems with the 
study medication  or development of intercurrent vaginal symptoms.  Any of the following 
activities will be performed at the discretion of the site PI:  
• Medical history will be reviewed and updated as appropriate.  
• Interim sexual history since the last clinic visit will be collected.  
• Vaginal symptoms will be assessed.    
• A urine pregnancy test will be performed on all participants  of childbearing potential . 
• Compliance with the study protocol criteria will be assessed; any used and unused  study IP 
packaging will be collected as relevant and recorded.  
• Participant memory aid will be collected and reviewed.  
• All concomitant medications taken since the last study visit  will be recorded on the 
appropriate DCF . Previously recorded medications will be updated  as appropriate . 
• Study personnel will discuss  with participants and assess and  record all AE s/SAEs.  
Previously recorded AEs/SAEs will be updated as appropriate . 
• If clinically indicated, a targeted physical examination will be performed by a qualified study  
clinician.  
• A pelvic examination to include examination of external genitalia will be conducted,  and 
swabs and sample s taken for analysis of Amsel cri teria; KOH and saline microscopy for 
identification of yeast forms, trichomonas, and clue cells ; and Gram staining . Instructions for 
obtaining vaginal swab specimens for these assessments are outlined in  the protocol specific 
MOP . Gram stain Nugent scoring will be conducted in the Central Laboratory; all other 
testing will be conducted locally.  
• Participan ts with clinical evidence of VVC based on vulvovaginal signs (edema, erythema, 
and/or excoriation) and symptoms (vulvovaginal itching, burning, and/or irritation) will have 
a confirmatory vaginal Candida culture and treated as appropriate  with oral flucona zole.  
Participants who cannot take oral fluconazole will be terminated from the study.  
• Vulvovaginal signs will be assessed and graded by [CONTACT_926], as applicable. A clinical 
determination for BV recurrence will be made based on evaluation of Amsel criteria . The 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  47 
CONFIDENTIAL  
 presence of >2 of 4 Amsel criteria is required for a diagnosis of BV recurrence.  Participants 
with a clinical diagnosis of BV recurrence will complete a satisfaction questionnaire and will 
be terminated from the study.  
• Participants who are negative for BV determined as ≤ 2 of 4 Amsel criteria will be scheduled 
for the next return visit , blinded IP and a memory aid will be provided  as needed , and 
protocol requirements and dosing instructions reviewed.  
 Protocol Deviations  
A protocol deviation (PD) is any noncompliance with the clinical trial protocol, GCP, or MOP 
requirements.  The noncompliance may be either on the part of the participant , the investigator, 
or the study site staff.  As a result of deviations, corrective ac tions should be developed by [CONTACT_651133] E6:  
4.[ADDRESS_873273] be promptly reported to DMID , 
via the SDCC ’s electronic study database . 
NOTE:  Those sites participating in trials with a designated “central unit” will follow the 
reporting requirements specified in their protocols and MOPs.  The “central unit” will be 
responsible for submission of the PD to TRI/ICON  DMID  CROM S.   
All PDs, as defined above, must be addressed in study participant  DCFs .  A completed copy of 
the DMID  PD Form must be maintained in the Regulatory File, as well as i n the participant 's 
study folder .  PDs must be submitted  to the central IRB /IEC  and to the local IRB/IEC per their 
guidelines.  The site PI [INVESTIGATOR_651097].  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  48 
CONFIDENTIAL  
 
 DESCRIPTION OF CLINICAL AND LABORATORY 
EV ALUATIONS  
 Clinical Evaluations  
Complete medical history will be obtained by [CONTACT_651134] V0 and will be 
updated at each clinic visit. At follow -up visits, an interim medical history will be obtained by 
[CONTACT_651135].  
Sexual history will be obtained by [CONTACT_651134] V0. Participants  will be 
queried at V1 thru V 4 regarding sexual activity since the previous clinic visit.  
Medications history (concomitant medications) will include a review of a ll current medications  
taken  30 days prior to the screening visit  and through study completion . Prescription and over -
the-counter drugs will be included as well as vitamins, herbs and supplements. Assessment of 
eligibility will also include a review of all  permitted and prohibited medications per the 
Participant  Inclusion and Exclusion Criteria (see Section  5). 
A pelvic examination  including examination of external genitalia , will be performed at the 
screening  visit, V0. A targeted physical examination  including height and weight will be 
performed  at enrollment visit, V1, and  if clinically indicated  for follow -up visits , and pelvic 
exam ination  will be performed at the enrollment visit, V1, and at each of the follow -up visits, V 2 
thru V 4. All physical examinations will be performed by a qualified study clinician.    
Study IP, memory aid s and instructions will be provided to participants at the enrollment visit, 
V1 and return visits, V2 and V3.  Compliance with the study IP will be assess ed at all follow -up 
visits and contacts  (V2-V4 and as needed at unscheduled and early termination visits) and 
recorded.   
A pelvic examination and vulvovaginal examination  for the evaluation of the vulva, vagina, and 
cervix will be performed by [CONTACT_7880] [INVESTIGATOR_261959] .  At the screening visi t, V0, these 
examinations will be done for the purpose of determining eligibility.  At the enrollment visit , V1, 
Follow -up visits (V2 -V4), or an u nscheduled visit these examinations will be done for the 
purpose of evaluating treatment eff icacy and the pres ence of treat ment -emergent AEs (TEAEs).    
Pelvic Examination:  
During  the initial  screening visit , V0 pelvic exam ination , the clinical diagnosis of BV will be 
based on the presence of 3/4  of the following Amsel criteria : 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873274] eristic of BV ;  
2. A fishy odor of the vaginal discharge with the addition of a drop of 10% KOH (positive 
whiff test );  
3. Clue cells ≥ 20% of the total vaginal squamous epi[INVESTIGATOR_651098] ; 
4. Vaginal fluid pH >4.5 . 
Instructions for obtaining and determining the presence of Amsel clinical criteria can be found in 
the protocol -specific MOP . 
During the enrollment  visit’s, V1 pelvic exam ination , a clinical determination to confirm BV 
cure following metronidazole  or CDC -recommended  BV treatment  induction  will be determined 
by ≤ 2 of 4 Amsel  criteria  and absence of BV symptoms  (defined as absence of homogenous 
discha rge and odor) .  
At all other follow -up visit s on suppressive study IP (V2-V4), a clinical determination of BV 
recurrence will be  determined as  > 2 of 4  Amsel criteria  by [CONTACT_388053] .  
For the enrollment V1 or follow -up (V2 – V4) visits, participants will be scheduled  outside of 
menses  as soon as possible after cessation of  menstruation .  
At all follow -up visits (V2 -V4), a clinical diagnosis of VVC  will be based on vulvovaginal signs 
(edema, erythema, and excoriation ) and symptoms ( itching, burning, and irritation ) and a 
positive KOH microscopy with  identification of yeast forms (hyphae/pseudohyphae) or budding 
yeasts . A confirmatory Candida culture with speciation will also be performed ; Candida culture 
in the setting of incomplete criteria for the clinical diagnosis may be obtained at the discretion of 
the study clinician .  
7.1.1 Assessment of Concomitant Medications/Treatments  other than Study Product  
Administration of any medications, therapi[INVESTIGATOR_014], or vaccines will be recorded on the appropriate 
DCF . Concomitant medications will include all medications taken [ADDRESS_873275] received study  IP and are subsequently diagnosed with a concomitant 
infection that requires systemic antibiotics will recei ve treatment according to the local clinic’s 
standard protocols  but will be considered non -evaluable for efficacy  and terminated from the 
study . However, participants who have received study IP and are subsequently diagnosed with 
VVC can remain in the stud y and be considered evaluable for efficacy if they are appropriate 
candidates for oral fluconazole therapy.   
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  50 
CONFIDENTIAL  
 At the discretion of the site PI, u se of new medication should prompt evaluation for the presence 
of a new diagnosis of chronic medical disease or  condition.  
Medications that might interfere  with the evaluation of the IP should not be used unless 
absolutely necessary.  
Refer to Section 5 (Selection of Participa nts and Study Enrollment and Withdrawal ) for 
medications that are prohibited fo r study eligibility and throughout study participation.  
7.1.2 Assessment of Participant  Compliance with Study Intervention/Investigational 
Product  
The TOL -463 Insert  and placebo are  inserted by [CONTACT_87755] . 
At each follow up visit , V2 through V 4, participants will be asked to bring the study IP 
packaging , unused  inserts  (if any)  and memory aid corresponding to the return visit  (V2, V3 or 
V4) to the study personnel.  Study personnel will review adherence to the study IP schedule with 
the participants , including the participant  memory aid , and record this on the appropriate DCF  at 
each follow -up visit  and any unscheduled visits.  Study personnel will record the number of  
unused  insert s and empty packaging  returned  at each of the follow -up visits, V [ADDRESS_873276] 
the participant’s memory aid  after documenting compliance.   Refer to 4.4 for instructions on 
handling of r eturned study IP packaging .  
 Laboratory Evaluations  
7.2.1 Clinical Laboratory Evaluations  
At the screening visit,  V0, diagnostic laboratory tests for determination of C. trachomatis , N. 
gonorrhoeae , and T. vaginalis  (NAATs) will be performed locally.  Vaginal Gram stain Nugent 
scoring for microbiologic confirmation  of clinical findings will be conducted in the Central  
Laboratory. BD Max baseline testing will be conducted at a certified laboratory .  Instructions for 
obtaining vaginal swab specimens for these assessments are outlined in the protocol -specific 
MOP .   
A urine pregnancy test will be performed at all visits on all participants  of childbearing potential.  
Screening and enrollment visit r esults must be negative and known prior to randomization on 
V1. 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873277] a confirmatory culture for vaginal 
Candida with speciation performed locally.    
Nugent Criteria  for Determination of BV : 
A vaginal swab for microbiolo gic assessment of BV by [CONTACT_515079] c riteria should be performed . 
The Nugent s core utilizes a 0 -10 point scale for evaluation of vaginal flora and is based on the 
weighted sum score of the following three  bacterial morphotypes calculated from the slide exam 
under oil immersion (1000x) : 
• Lactobacillus : Large Gram -negative  rods 
• Gardnerella /Bacteroides  spp: thin, curved, G ram-variable rods  
• Mobiluncus  spp: t hin, curved, Gram -variable rods  
The Nugent score is interpreted as follows: 0 -3 normal; 4 -6 intermediate; and 7 -10 BV. For the 
purposes of this study, a Nugent score of ≥7 will b e used to define a microbiologic recurrence of 
BV for ancillary analysis . 
 
Candida  Culture for Determination of VVC:  
For participants with a clinical diagnosis of VVC at V 1-V4, a vaginal swab  should also be taken 
for confirmation  of Candida  by [CONTACT_651136] .  See the protocol -specific MOP for 
further details.  
 Laboratory Specimen Preparation, Handling, and Storage  
Specimen preparation, handling, and storage will be done according to local clinic SOPs. The 
enrolled participants study specimens collected for the BD Max testing  and gram stain slides  will 
be stored until the end of the study and then destroyed. Likewise , for enrolled participants, t he 
additional vaginal swab collection  and non-albicans Candida strain culture s only  will be stored 
for future use .  Additional details can be found in the protocol -specific MOP.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  52 
CONFIDENTIAL  
 
 Laboratory Specimen Ship pi[INVESTIGATOR_651099] (IATA) requirements. The Central Laboratory 
address is as follows:  
 
UAB Infectious Diseases Laboratory  
[ADDRESS_873278] South  
ZRB 242  
Birmingham, AL [ZIP_CODE]  
Additional details can be found in the protocol -specific MOP.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  53 
CONFIDENTIAL  
 
 ASSESSMENT OF SAFETY  
 Assessing and Recording  Safety Parameters  
Safety will be monitored throughout the study by [CONTACT_651137] n; and 
participant  reporting.  Safety will be assessed by [CONTACT_12218]:  
1. Serious AEs  occurring after randomization and from the time of the IP dose through V4. 
2. Non-serious AEs occurring after randomization and from the time of the IP dose through 
V4. 
8.1.1 Adverse Events  (AEs) 
ICH E6 defines an AE as any untoward medical occurrence in a participant  or clinical 
investigation participant  administered a pharmaceutical product regardless of its causal 
relationship to the study treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of medicinal (investigational) product.  The occurrence of an AE may come to the  attention 
of study personnel during study visits and interviews of a study participant  presenting for 
medical care, or upon review by a study monitor.  
All AEs not meeting the criteria for “serious adverse events” should be captured on the 
appropriated CR F.  Information to be collected for AEs includes event description, date of onset, 
clinician’s assessment of severity , relationship to IP (assessed only by [CONTACT_12213] a diagnosis , or his/her designee ), date of resolution /stabilization of the event.   
All AEs occurring while on study must be documented appropriately regardless of relationship. 
All AEs will be followed to adequate resolution.  
Any medical condition that is present at the time that the participant  is screened will be 
considered as baseline and not reported as an AE.  However, if it deteriorates at any time during 
the study , it should be recorded as an AE.  
All AEs must be graded f or severity and relationship to IP. 
 Adverse Events Grading  
FDA defines an AE as any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug -related. All AEs  (laboratory and clinical symptoms)  will 
be graded f or severity and assessed for relationship to IP (see definitions) . AEs characterized as 
intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  The start and stop date 
of each reported AE will be recorded on the appropriate DCF  and elect ronic case report form, 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  54 
CONFIDENTIAL  
 (eCRF ). Changes in the severity of an AE will be documented to allow an assessment of the 
duration of the event at each level of intensity.  
Severity of Event:    
All AEs will be assessed by [CONTACT_418025] a protocol -defined grading system  (refer to 
Appendix B ).  For events not included in the protocol -defined grading system, the following 
guidelines will be u sed to quantify severity:  
• Mild (Grade 1) :  Events that are usually transient and may require  only minimal or no 
treatment and generally do not interfere with the participant ’s daily  activities.  
• Moderate (Grade 2) :  Events that are usually alleviated with a dditional specific therapeutic 
intervention .  The event interferes with usual activities of daily living, causing discomfort but 
poses no significant or permanent risk of harm to the research participant.  
• Severe (Grade 3) :  Events interrupt usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.   Severe events are usually 
incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865].  
Relationship to Study Product s: The clinician’s assessment of the AE’s relati onship  to IP will 
be done by [CONTACT_8703] a n assessment , or his/her designee,  and 
the assessment will be part of the documentation process .  Whether the AE is related or not,  is 
not a factor in determining what is or is not  reported in this trial.  If there is any doubt as to 
whether a clinical observation is an AE, the event should be reported.   
In a clinical trial, the study medication  must always be suspect.  The relationship to study 
medication will be assessed for AEs using the terms  related or not related:  
• Related  – There is a reasonable possibility that the study product caused the AE. Reasonable 
possibility means that there is evidence to suggest a causal relationship between the study 
medication  and the AE. 
• Not Related  – There is not a reasonable possibility that the administration of the study 
medication  caused the event.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  55 
CONFIDENTIAL  
 8.1.2 Serious Adverse Events  (SAEs)  
An AE or suspected adverse reaction is considered  a SAE if, in the view of either the  site PI [INVESTIGATOR_149057], it res ults in any of the following outcomes:  
• Death,  
• a life -threatening adverse event*,  
• inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
• a congenital anomaly/birth defect.   
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical judgment 
they may jeopardize the participant  and may require medical or surgical interven tion to 
prevent one of the outcomes listed in this definition.  Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, blood dyscrasias or convulsions that do not result in inpatient hos pi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.  
* Life-threatening adverse event. An AE is considered “life -threatening” if, in the view of either 
the site PI [INVESTIGATOR_10157], its occurrence places the participant  at immediate risk of death.  It does not 
include an AE that, had it occurred in a more severe form, might have caused death.  
All SAEs will be:  
• Assessed for severity and relationship to study product  and alternate etiology  (if not related 
to study product ) by a  licensed study physician or by [CONTACT_149088] [INVESTIGATOR_651100], ( SubI ). 
• Recorded on the appropriate SAE DCF  and eCRF.  
• Followed through resolution  by a licensed study physician .  
• Reviewed and evaluated by [CONTACT_122830] , an Independent Safety Monit or (ISM) (as deemed 
necessary), the DSMB (periodic review unless related), and the IRB /IEC . 
 Specification of Safety Parameters  
Safety specification s are noted in Section 8.1 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873279] be submitted immediately 
(within 24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
 
DMID Pharmacovigilance Group  
Clinical Research Operations and M anagement Support (CROMS)  
[ADDRESS_873280]. Suite 650  
Bethesda, MD [ZIP_CODE], [LOCATION_003]  
SAE Hot Line: 1 -[PHONE_889] (US) or 1 -[PHONE_1728] (outside US)  
SAE FAX Number: 1 -[PHONE_1729] (US) or 1 -[PHONE_891] (outside US)  
SAE Email Address: [EMAIL_1393]  
In addition to the SAE form, select SAE data fields must also be entered into the Advantage  
eClinical® system . Please see the protocol -specific MOP for details regarding this procedure.  
Other supporting documentation of the event may be requested by [CONTACT_154385].  
The site will send a copy of the SAE report(s) to the ISM (as deemed necessary) when they are 
provided to the DMID Pharmacovigilance Group.  The DMID Medical Monitor and DMID 
Clinical Project Manager will be notified of the SAE by [CONTACT_651138] e Group.  
The DMID Medical Monitor will review and assess the SAE for regulatory reporting and 
potential impact on study participant  safety and protocol conduct.  
At any time after completion of the study, if the site PI [INVESTIGATOR_651101] , the site PI [INVESTIGATOR_651102].  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873281] a causal relationship between the study intervention and the 
AE.  DMID w ill submit an IND safety report to the FDA and will notify all participating site PIs 
(i.e., all PIs to whom the sponsor is providing drug under its IND or under any PI’s IND ) of 
potential serious risks from clinical studies or any other source, as soon as possible .  DMID will 
report to the FDA any unexpected fatal or life -threatening suspected adverse reaction as soon as 
possible, but in no case later than 7 calendar days after the sponsor’s initial receipt of the 
information.  If the event is not f atal or life -threatening the IND safety report will be submitted 
within  [ADDRESS_873282].   
All SAEs designated as “not related” to study product(s), will be reported to the FDA at least 
annually in a summary format.  
8.3.[ADDRESS_873283] with pregnant study 
participant s to obtain pregnancy outcome information. The pregnant participant  will be followed 
until delivery or until the end of pregn ancy (in the case of miscarriage or pregnancy termination). 
Infants born to these study participant s will also be monitored for SAEs (congenital anomalies or 
other birth defects) and  other complications for up to two months after birth. Pregnancy reporting  
forms will include  collecting data on the following information:  
• prior maternal history including congenital abnormalities or pregnancy complications;  
• estimated and actual date of delivery or end of pregnancy;  
• pregnancy outcome (live birth, stillbirth, miscarriage or elective termination);  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  58 
CONFIDENTIAL  
 • mode of delivery;  
• maternal complications; and  
• neonatal complications (i.e., lethal or nonlethal congenital abnormality).  
Pregnancies occurring in study participants  will be reported via Advantage  eClinical  on the 
Pregn ancy Report form .   
 Type and Duration of Follow -up of Participants  after Adverse 
Events  
AEs and SAEs will be followed from  the time of study treatment through resolution even if this 
extends beyond the study  reporting period, V 4. Resolution of an AE/SAE is defined as the return 
to pretreatment status or stabilization of the condition with the expectation that it will remain 
chronic.  
Follow -up procedures, evaluations, and outcomes will be recorded on the appropriate DCF . 
 Procedures to be Followed in the Event of Abnormal Laboratory 
Test Values or Abnormal Clinical Findings  
The site PI [INVESTIGATOR_651103] s/SAEs that are observed or 
reported during the study, regardless of their relationship to study product. AE s/SAEs, abnormal 
clinical laboratory values, or abnormal clinical findings  will be documented, reported, and 
followed appropriately .  
 Halting Rules  
Further enrollment will be halted for DSMB review/recommendation if any of the following are 
reported .  
If one or more participants  experience a n SAE judged by [CONTACT_651139] 3 and related to study IP 
An overall pattern of symptomatic, clinical, or laboratory events that the DMID Medical Monitor 
or DSMB consider associated with study drug and that may appear minor in terms of individual 
events, but that may collectively represent a serious potential concern for safety  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873284] 
during the entire study, as applicable.  
 Safety Oversight (ISM  plus DSMB)  
8.7.1 Independent Safety Monitor (ISM)  
An ISM at each clinical research site will oversee the safety of research participants  at that site 
and will provide independent written evaluation of SAEs and related Grade [ADDRESS_873285] (DSMB)  
Safety overs ight will be conducted by a DSMB that is an independent group of experts that 
monitor s participant  safety and advise s DMID . The DSMB members will be separate and 
independent of study personnel participating in this study  and should not have scientific, 
financial or other conflict of interest related to this study . The DSMB  will consist of  members  
with appropriate expertise to contribute to the interpretation of the data from this trial.  
The DSMB will review study progress and participant clinical and safety data at the following 
time points:  
• An initial organizational meeting will be held prior to the study starting and enrollment of 
participants.  
• At specified times during the course of study as defined in the DSMB Charter .   
• Ad hoc meeting convened to address a specific safety concern such as when a halting rule 
is met  or for immediate concerns regarding observations during the study.  
• A final closeout review will be held within six months after the database is locked to 
review all cu mulative safety data . 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  60 
CONFIDENTIAL  
 The DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the DSMB. Procedures for DSMB reviews/meetings will be defined in 
the charter. Reports may include enrollment and d emographic information, medical history, 
concomitant medications, physical assessments, clinical laboratory values, dosing compliance, 
and solicited and unsolicited AE/SAEs.   As an outcome of each review/meeting, the DSMB will 
make a recommendation as to t he advi sability of proceeding with the study administrations (as 
applicable), and to continue, modify, or terminate the study.   
DMID or the DSMB chair may convene the DSMB on an ad hoc basis according to protocol 
criteria or if there are immediate concerns  regarding observations during the course of the study. 
The DMID Medical Monitor is empowered to stop enrollment and study treatment if AEs that 
meet the halting criteria are reported. The DMID Medical Monitor  and the ISM (as deemed 
necessary)  will be resp onsible fo r reviewing SAEs in real time. The DSMB will review SAEs on 
a regular basis and ad hoc during the study.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873286]  
Each site PI [INVESTIGATOR_651104](s) and 
send supporting documentation to the DMID before initiating recruitment of participants .  The 
investigator will submit applicable information to the IRB on which it relies for the review, to 
conduct the review in accordance with 45 CF R 46, ICH E6 GCP, and as applicable,  21 CFR 56 
(Institutional Review Boards) and 21 CFR 50 (Protection of Human Subjects) , other federal, 
state, and l ocal regulations. The IRB must be registered with OHRP as applicable to the research.  
DMID  must receive t he documentation that verifies IRB  approval for this protocol, informed 
consent documents  (optional p re-screen  ICF, SIC and EIC) , and upon request any recruitment 
material and  handouts or surveys intended for the participant s, prior to the recruitment , 
screening,  and enrollment of participant s. 
Should amendments to the protocol or consent form s be required, the amendments will be 
approved by [CONTACT_651140] [INVESTIGATOR_651105].   IRB review and 
approval will occur at le ast annually throughout the enrollment and follow -up of participants and 
may cease if annual review is no longer required by [CONTACT_149091].  The PI 
[INVESTIGATOR_154337], as applicable to the IRB 
policy.  
Each institution engaged in this research will hold a current FWA issued by [CONTACT_651141].   The FWA number will be provided to DMID.  
A single IRB of re cord will be accountable for compliance with regulatory requirements for this 
multi -centered study, at participating sites .  A Reliance Agreement, also called an IRB 
Authorization Agreement  will be required  to be signed by [CONTACT_651142] y and 
permits the local  IRB to cede review to the single  IRB.  The IRB Authorization Agreement  will 
set forth the specific responsibilities of the IRB and each participating site.  Participating sites 
will t hen rely on the IRB of record to satisfy the regulatory requirements relevant to the IRB 
review. The participating sites will maintain essential required documentation of IRB reviews, 
approvals, and correspondence, and must provide copi[INVESTIGATOR_651106] r egulatory authorities upon request.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  62 
CONFIDENTIAL  
 
 Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the indi vidual’s trial participation.  There will be two consen t 
forms  and an optional pre -screen consent form :  SIC for the screening procedures (determination 
of eligibility confirmed by [CONTACT_651143]) ; an EIC for the full study ; and an optional pre -screen consent 
form to aid in initial BV diagnosis .  At the enrollment  visit, V1,  upon confirmation of BV cure 
and confirmation of eligibility, the participant will then need to be consented using the EIC prior 
to continuation.   Partic ipants will receive a concise and focused presentation of key information 
about the clinical trial, verbally and with the written consent form s. The explanation will be 
organized and presented in lay terminology and language that facilitates understanding why the 
individual  might or might not want to participate.  
The site PI,  or design ated study staff  will describe the protocol to potential participants  face-to-
face. The key information about the purpose of the study, the procedures and experimental 
aspects of the study, risks and discomforts, any expected benefits to the participant,  and 
alternative treatment will be presented to the participant .   
Participant s will also receive an explanation that the trial involves research, and a detailed 
summary of the proposed study procedures and study interventions/ medications .  This will 
include aspects of the trial that are experimental, the probability for rand om assignment to Tol-
463 Insert vs. placebo , any expected benefits, all possible risks (including a statement that the 
study medication  may involve risks to the participant  or to the embryo or fetus, if the participant  
may become pregnant, that are current ly unforeseeable), the expected duration of the 
participan t’s participation in the trial, alternative procedures that may be available and the 
important potential benefits and risks of these available alternative procedures.  
Participan ts will be informed that they will be notified in a timely manner if information 
becomes available that may be relevant to their willingness to continue participation in the trial. 
Participant s will receive an explanation as to whether any compensation and any medical 
treatme nts are available if injury occurs, and, if so, what they consist of, or where further 
information may be obtained. Participant s will be informed of the anticipated financial expenses, 
if any, to the participant  for participating in the screening and enrol lment visits , as well as any 
anticipated prorated payments, if any, to the participant  for participating in the trial. They will be 
informed of whom to contact (e.g., the investigator) for answers to any questions relating to the 
research project.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  63 
CONFIDENTIAL  
 Information will also include the foreseeable circumstances and/or reasons under which the 
participant’s  participation in the trial may be terminated. The participan ts will be informed that 
participation is voluntary and that they are free to withdraw from  the study for any reason at any 
time without penalty or loss of benefits to which the participan t is otherwise entitled.   
The extent of the confidentiality of the participant s’ records will be defined, and participan ts will 
be informed that applicable da ta protection legislation will be followed. Participant s will be 
informed that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be 
granted direct access to the participan t’s original medical records for verification of clinical t rial 
procedures and/or data without violating the confidentiality of the participan t, to the extent 
permitted by [CONTACT_4913], and that, by [CONTACT_2960] a written informed consent 
form  (ICF) , the participan t is authorizing such access.  
Participant s will be informed that records identifying the participan t will be kept confidential, 
and, to the extent permitted by [CONTACT_29695]/or regulations, will not be made publicly 
available and, if the results of the trial are published, the  participan t’s identity will remain 
confidential. Participant s will be informed whether private information collected from this 
research and/or specimens will be used for additional research, even if identifiers are removed.    
Participants  will be allowed sufficient time to consider participation in this research trial and  
have the opportunity to discuss this trial with their family, friends or legally authorized 
representative, or think about it prior to agreeing to participate.  
The SIC , EIC, and optional pre-screen consent  forms will be IRB -approved,  and participan ts will 
be asked to read and review the SIC form and if applicable, the EIC  or pre -screen consent form. 
Participant s must sign the SIC form prior to  starting any  screening study procedures  being done 
specifically for this trial.   Likewise, if applicable participants must sign the EIC form prior to 
starting any study procedures.  
Once signed, a copy of all consent form s will be given to the partic ipant for their records.  The 
partic ipant (s) may withdraw consent at any time throughout the course of the trial.  The rights 
and welfare of the participant (s) will be protected by [CONTACT_651144].  
Study staff may employ IRB approved recruitment efforts prior to obtaining the participant’s 
consent; however, before conducting protocol -specific screening activities  the SIC must be 
signed. Site clinical staff  may pre -screen via chart review and refer potential participants  to the 
study staff.   
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873287] vaginal swab specimens stored for 
future use  can still participate in the study.  If the participant consents, a n extra swab will b e 
collected  at V0 and if the participant is enrolled  and consents , one extra swab will be collected at 
all scheduled study visits .  Storage of samples is optional and not a requirement for the study. If 
the participant consents to storage and future use of  specimens, specimens will be stored 
appropriately  at a secure UAB facility .   
Participants will not be contact[CONTACT_651145].  Future testing 
on specimens will only occur to the extent authorized in each study site’s SIC and EIC (approved 
by [CONTACT_27321]) or as otherwise authorized under appli cable law and after review and approval 
by [CONTACT_122830] , the single IRB, and the IRB  of the researcher requesting the specimens.  
There will be no direct benefit to the participant from allowing the specimen s to be stored and 
used for future purposes.  However, the  results may provide information that will help in the 
diagnosis or treatment of future patients.   Refer to section 2.3.1  for potential participant risks 
when obta ining the vaginal swab specimen(s) for future use.   During this study, specimens saved 
for future use will be identified only by [CONTACT_651146].  Since part icipant study records are 
securely maintained by [CONTACT_464], there is minimal risk of breach of confidentiality.  At the end 
of the study, the future use specimens will be stored in a secure location and unlinked from any 
information that could connect th em with identifiable data from this stud y. 
The participant’s future use specimen will be kept indefinitely until it is used up or destroyed.  It 
may be used to develop new tests or products.  For example, the specimens could be used to test 
a new method fo r detecting vaginal infections, or to study why BV can cause pregnancy 
problems, or why BV can increase women’s risk of HIV infection.  In some instances, these may 
have potential commercial value.  No genetic testing or whole genetic sequencing will be 
performed on the samples.   
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873288] the study staff who will then notify the laboratory/specimen archive.  
The laboratory staff will then mark the specimens by [CONTACT_1583] a “Destroy” label and they will be 
destroyed at the end of this study or removed from storage and destroyed.  
 Exclusion of Women, Minorities,  and Children (Special Populations)  
This trial will be inclusive of female adults who meet the Participant  Inclusion/Exclusion 
Criteria, regardless of religion  or ethnic background. Should the outcome of this trial be deemed 
acceptable, additional trials m ay be initiated in other populations .  
Person s who are unable to fully participate in the study due to an in ability to provide informed 
consent will not be enrolled, for example  non-English speakers, children, illiterate or non -writing  
individuals.  This ex clusion is to ensure participants who cannot fully understand the implica tions 
of study participation due to language or cognitive barriers  are not recruited .   
 Participant  Confidentiality  
Participants will have code numbers and will not be identified by n ame.  Participant  
confidentiality is strictly held in trust by [CONTACT_421263] , their study staff, and the 
sponsor(s) and their agents. This confidentiality includes  the study protocol,  documentation, 
investigation data, participant ’s clinical i nformation, testing of biological specimens, and all 
other information generated during participation in the study. No information concerning the 
study , or the data generated from the study will be released to any unauthorized third party 
without prior wri tten approval of the DMID. Authorized third parties include OHRP or other 
government agencies as part of their duties, the FDA, single IRB, NIH, study staff, study 
monitors, Toltec, and designees.  Participant  confidentiality will be maintained when study 
results are published or discussed in conferences.   
All information provided by [CONTACT_941] s ponsor and all data and information generated by [CONTACT_651147] (other than a participant ’s me dical records) will be kept 
confidential by [CONTACT_7880] [INVESTIGATOR_421226].  This 
information and data will not be used by [CONTACT_7880] [INVESTIGATOR_651107]. These rest rictions do not apply to: (1) information that becomes 
publicly available through no fault of the site PI [INVESTIGATOR_29355]; (2) information that is 
necessary to disclose in confidence to an IRB solely for the evaluation of the trial ; (3) 
informatio n that is necessary to disclose in order to provide appropriate medical care to a study 
participant ; or (4) study results that may be published as described in Section 15.  If the 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873289]’s confidentiality provisions shall apply rather 
than this statement.  
The study monitor , or other authorized representatives of the sponsor , or governmental 
regulatory agencies  such as the FDA  may inspect all documents and records re quired to be 
maintained by [CONTACT_7880].  This  includ es, but is not limited to, medical records (office, clinic,  or 
hospi[INVESTIGATOR_307]) and pharmacy records for the participant s in this study. The participating s ites will 
permit access to such records.  
 Certificate of Confidentiality  
To protect privacy, we have received a Certificate of Confidentiality  (CoC).  With this CoC, the 
participating sites  cannot be forced to release information that may identify the research 
participant , even by a court subpoena, in any federal, state, or local civil, criminal, 
administrative, legislative, or other proceedings.  The  participating sites  will use the CoC to 
resist any demands for information that would identify the participant , except as explained 
below.  
The CoC cannot be used to resist a demand for information from personnel of the [LOCATION_002] 
Government that is use d for auditing or evaluation of federally funded projects, like this study, or 
for information that must be released in order to meet the requirements of the FDA.  
A CoC does not prevent the participant  from voluntarily releasing information about themselve s 
or their involvement in this research.  If any person or agency obtains a written consent to 
receive research information, then the researchers may not use the Certificate to withhold that 
information.   
The CoC does not prevent the participating sites  from reporting without the participant ’s consent, 
information that would identify the participant  as a participant in the study  regarding matters that 
must be legally reported including: child and elder abuse, sexual abuse, or wanting to harm 
themselves or others.   
The release of individual private information or specimens for other research will only occur if 
consent was obtained from the individual to whom the information, document, or biospecimen 
pertains , or for the purposes of other research that is in  compliance with applicable Federal 
regulations governing the protection of human participant s in research.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873290] to participant s for taking part in this trial.   
Procedures and treatment for clinical care may be billed to the participant , participant ’s insurance 
or third party.  Participant s may be compensated for their participation in this trial.  
Compensation will be in accorda nce with the local IRB’s policies and procedures, and subject  to 
IRB approval.  
If it is determined by [CONTACT_7880] [INVESTIGATOR_122767] a participant  as a direct result of the 
tests or treatments that are done for this trial, then referrals to appropr iate health care facilities 
will be provided to the participant .  Study staff will try to reduce, control, and treat any 
complications from this trial.  Immediate medical treatment may be provided by [CONTACT_202445].  No financial compensation will be provided to the participant  by [CONTACT_122845], NIH,  or by [CONTACT_651148].  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  68 
CONFIDENTIAL  
 
 STATISTICAL CONSIDERATIONS  
 Study Hypotheses  
The primary objective of the study is to evaluate the clinical efficacy of a twice -weekly 
application of the TOL -463 vaginal insert for the suppression of BV following successful 
induction with oral metronidazole  or other CDC -recommended  BV treatment  in women with a 
history of recurrent BV.  Clinical efficacy (suppression) is defined by [CONTACT_651125] (see Section 
3.3.1 ).   There is one planned hypothesis test with respect to the primary outcome measure.  The 
hypothesis test compares the pro portion of participants with recurrent BV by V4 between 
treatment arms.  The null hypothesis for the comparison is that there is no difference in cure rates 
between treatments, with a two -sided alternative.  The test will be conducted using the Pearson 
Chi-Square test at the 5% two -sided significance level.  
 Sample Size Considerations  
As detailed in Section 10.5, efficacy analyses will be performed in an evaluable subset of the 
enrolled population; this subset was used to derive the study’s sample size.  Assuming a 40% BV 
recurrence rate among women re ceiving placebo and a 50% reduction in recurrence among 
women treated with TOL -463 (i.e. 20% recurrence rate among TOL -463 recipi[INVESTIGATOR_840]) and a 1:[ADDRESS_873291] 85% power using the Chi -Square Test.  Assuming 80% of enrolled participants will be 
evaluable for the primary analysis, the enrollment target is set to 250 to achieve 200 evaluable 
participants.  
 Treatment Assignment Procedures  
10.3.1  Randomization Procedures  
Participants will be randomized 1:1 to receive one of two treatments: TOL -[ADDRESS_873292] of randomized treatment assignments will be prepared by [CONTACT_651149] ’ Internet Data Entry System (IDES). 
Advantage eClinical® will assign each participant to a blinded treatment number from the list 
after demographic and eligibility data have been entered. Each site will have a supply of blinded 
study dr ug kits pre -labeled with treatment numbers, each containing sufficient doses to treat a 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  69 
CONFIDENTIAL  
 participant for twelve weeks. The packaged study drug kits contain three , separate four -week kits 
to be dispensed to the participant at Enrollment V1 and Follow -ups V2 and V3 as applicable.  
Once a participant is assigned a treatment number, the corresponding kit will be distributed to the 
participant.  
Instructions for using the enrollment module are included in the IDES User’s Guide. Manual 
back -up randomization proced ures are provided in the MOP for use in case the site temporarily 
loses Internet access, or the online enrollment system is unavailable.  
The trial will use a site -stratified, permuted, blocked randomization scheme. Permuted blocked 
randomization is used to  avoid the potential for serious imbalance in the number of participants 
assigned to each group, which can occur in simple randomization procedures.  
10.3.[ADDRESS_873293] 
identifying the treatment identity (TOL -463 or placebo) in each kit to the Fisher staff responsible 
for preparing study drug kits. Clinicians, investigators, and all bl inded staff will not have access 
to this list until after the trial has ended.  
 Planned Interim Analyses  
10.4.1  Interim Safety Review  
The study will be monitored to determine if any of the safety halting rules de scribed in Section 
8.6 are met.  The DSMB will meet and review safety data and enrollment data at specified times 
during the course of study and at a study closeout meeting, as defined in  the Section 8.7.2  and 
the DSMB Charter.  
10.4.2  Interim Efficacy Review  
There are no planned interim efficacy analyses for this study.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  70 
CONFIDENTIAL  
 
 Final Analysis Plan  
A separate stati stical analysis plan , (SAP)  document will be generated which will contain the 
details of the analyses. This section outlines the major components of the analyses.  
10.5.1  Analysis Populations  
Safety Population:  This analysis population includes all randomized participants  who received at 
least one dose of study treatment.   
Modified Intent -to-Treat (mITT) Population:  This analysis population includes all randomized 
participants  who are evaluable .  
The mITT population will be used as the primary efficacy analysis population.  
Per-Protocol (PP) Population : This analysis population includes all randomized participants who 
met all inclusion/exclusion criteria  throughout the study , are evaluable (defined below), 
complied with the assigned IP, and returned to the study site for the TOC visit w ithin the 
specified window (Visit 4 [Window: Day 85-91]) or were followed up to  their diagnosis of 
recurrent BV .  
Evaluable is defined as follows:  
• Negative STI tests taken at baseline ( C. trachomatis , N. gonorrhoeae , or T. vaginalis );  
• For participants [ADDRESS_873294] prior to screening, or a P ap smear performed at 
screening /enrollment with normal result  
A participant is compliant with the study treatment if she misses < 2 non-consecutive doses of IP 
per month, as assessed by [CONTACT_651150] (V2, V3, V4).  
In the unl ikely event of an error in randomization  or IP administration (i.e., incorrect treatment), 
participants  will be grouped by [CONTACT_651151]. 
10.5.2  Baseline Characteristics  
Baseline and demographic characteristics will be summarized overall and by [CONTACT_3148]. For both 
continuous and categorical variables, appropriate summary statistics will be applied. For 
continuous variables , descriptive statistics will include the number of non -missing values, mean, 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873295] A® for preferred term and system organ class. The rate 
and exact 95% confidence intervals  (CIs)  of AEs in aggregate, as well as by [CONTACT_61132]® 
categories, will be computed. The number of SAEs is likely to be small in this study and will be 
reported by a detailed listing showing the type, MedDRA® coding, relevant dates ( IP 
administration dates and AE onset and resolution dates), severity, related ness, and outcome for 
each event.  
The occurrence of culture confirmed secondary VVC following initiation of study treatment and 
through the final study visit will be summarized in aggregate and by [CONTACT_1570].  
10.5.4  Efficacy Analysis Plan  
 Primary Efficacy A nalysis  
The primary efficacy analysis estimates the clinical efficacy rate of TOL -463. At each follow -up 
visit, the following Amsel criteria will be assessed:  
a. Positive KOH whiff test  
b. Homogeneous discharge characteristic of BV  
c. Clue cells ≥ 20% of vaginal squamous epi[INVESTIGATOR_1663]  
d. Vaginal pH > 4.5  
For the primary analysis, a participant is deemed to experience a recurrence of BV at a follow -up 
visit if >2 of the above criteria are met.   A participant has clinical suppression of BV if she 
meets two or fewer of the criteria at each observed follow -up visit through V4.  
The proportion of participants with recurrent BV up to and including V4 will be summarized 
overall and by [CONTACT_651152]-sided 95% Wilson CIs.  The primary analysis will 
be performed in the mITT analysis population. Secondary analyses of the primary outcome 
measure will be performed in the PP analysis population. Recurrence status of participants who 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  72 
CONFIDENTIAL  
 are withdrawn or drop out early before an observed recurrence will be imp uted; multiple 
imputation methods may be explored , and details will be provided in the SAP document.  
In addition, the rate of recurrence, which considers the amount of observed follow -up time for 
each participant, will be estimated within each treatment gr oup along with corresponding 95% 
CIs.  Any additional sensitivity and/or corroborative analyses to be performed will be described 
in the separate SAP document.  
 Secondary Efficacy Analyses  
The secondary efficacy analyses are briefly described below. Secondary efficacy analyses will be 
performed in the mITT and PP analysis populations, where appropriate. Details of these analyses 
and any sensitivity analyses  will be specified in the separate SAP document.  
For the analysis of Secondary Objective 1, the median time to BV recurrence will be estimated 
by [CONTACT_229120] -Meier estimates.  For participants who experience BV 
recurrence by V4, the time of BV recurrence will be defined as the midpoint between the earliest 
time point of a positive BV diagnosis (post -baseline)  and the previous observed time -point. For 
participants  without BV recurrence at or before V4, the BV recurrence endpoint will be coded as  
censored, with time to recurre nce defined as the elapsed time from the first dose of IP, to the 
earliest of: V4 time -point,  the last observed time -point prior to loss to follow -up, or the time -
point at which the participant became ineligible for the particular analysis population.  
For the analysis of Secondary Objective 2, the proportion of participants experiencing vaginal 
symptoms as assessed by [CONTACT_651153], by 
[CONTACT_651154], and by [CONTACT_1570].  
For the analysis of Secondar y Objective 3,  responses to the satisfaction questionnaire will be 
summarized overall and by [CONTACT_1570]. Categorical responses will be summarized using 
contingency tables and/or odds ratios, while continuous responses will be summarized using 
measures  of central tendency such as the mean or median, and measures of dispersion such as the 
standard deviation or interquartile range.  
 Exploratory  and Other Efficacy Analyses  
Descriptions of the analyses to assess the exploratory objective as well as other ana lyses that will 
support the primary and secondary efficacy analyses will be provided in the separate SAP 
document.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  73 
CONFIDENTIAL  
 Examples of additional analyses that will support the primary and secondary efficacy analyses 
will include, but not limited to, summaries of Nugent scores by [CONTACT_3232], and 
explorations of recurrences by [CONTACT_651155].  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  74 
CONFIDENTIAL  
 
 SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research reco rds for this trial, in 
compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the 
protection of confidentiality of participant s. Each participating site will permit authorized 
representatives of the DMID, its designees, and appropriate regulatory agencies to examine (and 
when required by [CONTACT_1289], to copy) clinical study records for the purposes of quality 
assurance (QA) reviews, audits, monitor ing, and evaluation of the study safety and progress. 
These representatives will be permitted access to all source data  and source documents , which 
include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, 
memoranda,  participants’ evaluation checklists, pharmacy dispensing records, recorded data 
from automated instruments, copi[INVESTIGATOR_71975], microfiches, photographic negatives, microfilm or magnetic me dia, x -rays, and 
participant  files and records kept at the pharmacy, at the laboratories, and medico -technical 
departments involved in the clinical trial. Source data are all information, original records of 
clinical findings, observations, or other activi ties in a clinical trial necessary for the 
reconstruction and evaluation of the trial.   DCF’s  will be provided by [CONTACT_80938].  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  75 
CONFIDENTIAL  
 
 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted site quality management plan, each participating site  is 
responsible for conducting routine QA and quality control (QC) activities to internally monitor 
study progress and protocol compliance.  The site PI [INVESTIGATOR_71464] -
related sites, source data/ DCFs , and reports for the purpose of monitoring and auditing by [CONTACT_103], and inspection by [CONTACT_3482].  The site PI [INVESTIGATOR_366454].  
The SDCC will implem ent QC procedures beginning with the data entry system and generate 
data QC checks that will be run on the database.  Any missing data or data anomalies will be 
communicated to the participating site (s) for clarification and resolution.  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873296] and m aintain data for 
each participant screened and enrolled in the study.  All DCFs  should be completed in a neat, 
legible manner to ensure accurate interpretation of data.  Black or blue ink is required to ensure 
clarity of reproduced copi[INVESTIGATOR_014].  When making a c hange or correction, cross out the original entry 
with a single line and initial and date the change.  Do not erase, overwrite, or use correction fluid 
or tap on the original.   
Data reported in the eCRF derived from the source DCFs  should be consistent or  the 
discrepancies should be explained.  
The sponsor and/or its designee will provide guidance to the site PIs and other study personnel 
on making corrections to the DCFs  and eCRF.  
 Data Coordinating Center/Biostatistician Responsibilities  
All DCFs  and labor atory reports must be reviewed by [CONTACT_452459], 
who will ensure that they are accurate and complete.  A Es must be recorded on the appropriate 
DCF , assessed for severity and relationship, and reviewed by [CONTACT_7880] [INVESTIGATOR_241543]/her designee . 
Data collection is the responsibility of the study personnel at the participating clinical study site 
under the supervision of the site PI.  During the study, the site PI [INVESTIGATOR_149064].  
The SDCC  for this study will be responsible for data management, quality review, analysis, and 
reporting of the study data.  
 Data Capture Methods  
Clinical data (including, but not limited to,  AE/SAEs, concomitant medications, medical history, 
physical assessments, and clinical laboratory values ) will be collected on DCF s by [CONTACT_12240] a [ADDRESS_873297] protection and 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873298] results,  and IP inventory  records will be retained  for 2 years after a marketing 
application is approved for the IP for the indication for which it is being investigated; or, if no 
application is to be filed or if the application is not approved for the IP, until 2 years after the 
investigation is discontinued and the FDA has been notified. These documents will be retained  
for a longer period, however, if required by [CONTACT_427]. SICs and EICs for future use will 
be maintained as long as the sample/specimen exists.  
No records will be destroyed without the written consent of the sponsor. It is the responsibility of 
the sponsor to inform the site PI [INVESTIGATOR_135830]. The 
participating sites must contact [CONTACT_651156].  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873299]  protections study and laboratory 
procedures, study intervention administration, and data collection processes are of high quality 
and meet sponsor, ICH/GCP guidelines and applicable regulations,  and that this trial is 
conducted in accordance with the protocol, protocol -specific MOP and applicable sponsor SOPs .  
A separate monitoring plan document should be developed to describe who will conduct the 
monitoring, at what frequency monitoring will be  done, and what level of detail monitoring will 
be conducted.  Most DMID sponsored studies are monitored by [CONTACT_533804]/ICON DMID CROMS, and 
the clinical monitoring plan is written jointly by [CONTACT_651157]/ICON.   Preference is given to a 
separate monitoring plan to  be agreed upon with the Office of Clinical Research Affairs 
(OCRA), which will describe protocol -specific items to be monitored.   The monitoring plan must 
include the number of participant  charts to be reviewed, which/what proportion of data fields and 
what will be monitored, who will be responsible for conducting the monitoring visits, and who 
will be responsible for ensuring that monitoring findings are addressed.  
Site visits will be made at standard intervals as defined by  [CONTACT_651158].  Monitoring visits will include, but are not limited to, 
review of regulatory files, accountability records, eCRFs, informed consent forms  (SIC and 
EIC) , medical and laboratory reports, and protocol and GCP compli ance.  Site monitors will 
have access to each participating site, study personnel, and all study documentation  according to 
the DMID -approved monitoring plan.  Study monitors will meet with site PIs to discuss any 
problems and actions to be taken  and will document site visit findings and discussions.  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873300] submitted  for 
them to the National Library of Medicine’s PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) 
an electronic version of their final, peer -reviewed manuscripts upon acceptance for publication, 
to be made publicly available no later than [ADDRESS_873301] be accessible to the public on PubMed Central no 
later than 12 months after publication.  
Refer to:  
• NIH Public Access Policy, http://publicaccess.nih.gov/  
• NIH Office of Extramural Research (OER) Grants and Funding, 
http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_873302] applied for certification of delayed posting.  
As part of the result posting a copy of this protocol (and its amendments) and a copy of the SAP 
will be posted on ClincialTrials.gov.  
For this trial  the responsible party is NIAID  which will  register the trial and post results.   
The responsible party does not plan to request certification of delayed posting.  
Refer to:  
• Public Law 110 -85, Section 801, Clinical Trial Databases  
• 42CFR11  
• NIH NOT -OD-16-149 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  80 
CONFIDENTIAL  
 
 LITERATURE REFERENCES  
1. Muzny, C. and J. Schwebke, Biofilms: an underappreciated mechanism of treatment 
failure and recurrence in vaginal infections.  Clin Infect Dis, 2015. 61(4): p. 601 -606. 
2. Diflucan [package insert]. [LOCATION_001], NY:  [COMPANY_007].  2018.  
3. Nuvessa [package insert].  Irvine, CA:  Allergan.  2016.  
4. Marrazzo, J., et al., Bacterial Vaginosis: Identifying Research Gaps Proceedings of a  
Workshop Sponsored by [CONTACT_32119]/NIH/NIAID November 19 -20, 2008.  Sex Transm Dis, 
2010. 37(12): p. [ADDRESS_873303] Dis Rep, 2015. 
17(6): p. 462.  
6. van de Wijgert, J., et al., Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, 
increase HIV -[ADDRESS_873304], 2008. 48(2): 
p. 203 -210. 
7. Bradshaw, C. and R. Brotman, Making inroads into improving treatment of bacterial 
vaginosis – striving for long -term cure.  BMC Infect Dis, 2015. 15(1): p. 292.  
8. Allsworth, J. and J. Peipert, Prevalence of bacterial vaginosis: 2001 -2004 National Health 
and Nutrition Examination Survey data.  Obstet Gynecol, 2007. 109(1): p. 114 -120. 
9. Sobel, J., et al., Suppressive antibacterial therapy with 0.75% metronidazole vag inal gel 
to prevent recurrent bacterial vaginosis.  Am J Obstet Gynecol, 2006. 194(5): p. 1283 -
1289.  
10. CDC Sexually Transmitted Diseases Treatment Guidelines.  MMWR, 2015. 64(3): p. 1 -
138. 
11. Nyirjesy, P., Management of persistent vaginitis.  Obstet Gyneco l, 2014. 124(5): p. 1135 -
1146.  
12. Reichman, O., R. Akins, and J. Sobel, Boric acid addition to suppressive antimicrobial 
therapy for recurrent bacterial vaginosis.  Sex Transm Dis, 2009. 36(11): p. 732 -734. 
 
 
 
 
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  81 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 APPENDICES  
Schedule of Events  
Female Genital Grading Table for Physical Examination Findings  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  82 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
  
 Schedule of Events   
Table 17-1: Schedule of Events  
Procedures  Visit 0/V0  
Screening 
(Day -15 
to -8) Visit 1/V1  
Enrollment  
(Day 1)  Visit 
2/V2  
Follow -
up 
(Day s 
29-35) Visit 3/V3  
Follow -up 
(Day s 57-
63) Visit 
4/V4/TOC  
(Day s 85-
91) 
Unscheduled 
Visit  
Early  
Termination  
Visit  
Signed consent form1 X X      
Review of Inclusion/Exclusion criteria  X X      
Collection of Demographics  X       
Review of Medical History2, 3 X X X X X (X) X 
Review of Sexual History4 X X X X X (X) X 
Urine Pregnancy Test12 X X X X X (X) X 
Review of Concomitant Medications5 X X X X X (X) X 
Pelvic Examination3,6, 13 X X X X X (X) X 
Clinical assessment of Vulvovaginal 
signs  X X X X X (X) X 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  83 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Procedures  Visit 0/V0  
Screening 
(Day -15 
to -8) Visit 1/V1  
Enrollment  
(Day 1)  Visit 
2/V2  
Follow -
up 
(Day s 
29-35) Visit 3/V3  
Follow -up 
(Day s 57-
63) Visit 
4/V4/TOC  
(Day s 85-
91) 
Unscheduled 
Visit  
Early  
Termination  
Visit  
STI Screen ( C. trachomatis, N. 
gonorrhoeae , and T. vaginalis)7 X       
Clinical Determination of presence or 
absence of BV (Amsel Criteria)  X X X X X (X) X 
Gram stain evaluation/Nugent score for 
BV X X X X X (X) X 
BD Max Test  X X X X X  X 
Future Analysis Specimen Collection11 (X) (X) (X) (X) (X)  (X) 
Dispense Oral Metronidazole  (or other 
CDC -recommended  BV treatment)  X       
Randomization   X      
Targeted Physical Examination8  X (X) (X) (X) (X) (X) 
IP Dispensation, Participant Instructions   X X X  (X)  
Participant Memory Aid9  X X X X (X) X 
Reminder contact (for Visits 1, 2, and 3)   X X X    
Assessment of IP compliance  (via 
review of Memory Aid and IP return)    X X X (X) X 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  84 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Procedures  Visit 0/V0  
Screening 
(Day -15 
to -8) Visit 1/V1  
Enrollment  
(Day 1)  Visit 
2/V2  
Follow -
up 
(Day s 
29-35) Visit 3/V3  
Follow -up 
(Day s 57-
63) Visit 
4/V4/TOC  
(Day s 85-
91) 
Unscheduled 
Visit  
Early  
Termination  
Visit  
Participant Assessment of Vaginal 
Symptom s  X X X X X (X) X 
Candida Culture10  (X) (X) (X) (X) (X) (X) 
Assessment of AEs/SAEs     X X X (X) X 
Participant satisfaction questionnaire    (X) (X) X  X 
(X) – As indicated/appropriate.  
1. At V [ADDRESS_873305] complete medical  symptom  history; at subsequent visits, review and update medical symptom history as appropriate.  
3. A Pa p smear should be done at V0  for any participant who meets the following criteria and cannot provide documentation (which 
can include self -report) of a normal or ASCUS HPV negative Pap test within the prior 3 years: is 21 years of age or older and (a) has 
not had a hysterectomy or (b ) has had a hysterectomy and has a history of CIN grade 2+ (CIN2+) in the past [ADDRESS_873306] 30 days; at subsequent visits, coll ect interim sexual history since the last visit.  
5.  At V 0, collect concomitant medications taken in the last 30 days; at subsequent visits, collect concomitant medications taken sinc e 
the last visit.  
6. At V 1, one pelvic exam is performed  and if the parti cipant is enrolled and randomized  additional vaginal swabs are collected . 
7. Participants who test positive for STIs may be reconsidered for eligibility once the treatment course is complete.  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873307] 4 wee ks of the study.  At each of 
the follow -up visits, V 2-V4, the Memory Aid will be reviewed/ collected,  and a new Memory Aid for the next [ADDRESS_873308] forms, trichomonas and clue cells.  
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  86 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 
 Toxicity  Grading  Table 
Note:  the following table is adapted from the Division of AIDS Table for Grading the Severity 
of Adult and Pediatric Adverse Events, Addendum 1: Female Genital Grading Table for Use in  
Microbicide Studies (V1.0, November 2007)  
Table 17-2: Toxicity  Grading Table  
INDIVIDUAL SIGNS/SYMPTOMS  
PARAMETER  GRADE 0         
NORMAL  GRADE 1  
MILD  GRADE 2     
MODERATE  GRADE 3            
SEVERE  
GENERAL  
Odor  No 
complaint  Mild -moderate 
unpleasant 
odor Severe unpleasant 
odor NA 
PAIN AND TENDERNESS  
(Specify Area: Vulvar/Perineum, Vagina, Cervix (including cervical motion tenderness), 
Uterus, Adnexae, Pelvic/Lower Abdominal, or Ovulatory)  
*Note – if both pain and tenderness are present, only report the one with the most severe 
grade 
Pain* 1  None  Pain causing 
no or minimal 
interference 
with usual 
social & 
functional 
activities  Pain causing greater 
than minimal 
interference with 
usual social & 
functional activities 
or the need for non -
narcotic medication  Pain causing inability 
to perform usual 
social & functional 
activities or the need 
for narcotic 
medication OR 
hospi[INVESTIGATOR_059] (other 
than emergency room 
visit) indicated  
Tenderness* 1  None  Mild 
tenderness  Moderate 
tenderness  Severe tenderness  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  87 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Dyspareunia (pain with 
sexual activity)  None  Pain causing 
no or minimal 
interference 
with sexual 
function  Pain causing greater 
than minimal 
interference with 
sexual function  NA 
Dysmenorrhea/crampi[INVESTIGATOR_651108]  & 
functional 
activities  Pain causing greater 
than minimal 
interference with 
usual social & 
functional activities 
or the need for non -
narcotic medication  Pain causing inability 
to perform usual 
social or functional 
activities or the need 
for narcotic 
medic ation  
1 If pain or tenderness is included in the grading of another category (e.g., PID), it should not be 
graded again in the pain or tenderness category  
 
 
 
  
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  88 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 INDIVIDUAL SIGNS/SYMPTOMS  
PARAMETER  GRADE 0               
NORMAL  GRADE 1                
MILD  GRADE 2             
MODERATE  GRADE 3            
SEVERE  
GENITOURINARY SIGNS/SYMPTOMS – VULVA  
Vulvar/vaginal 
itching  None  Itching causing no, 
mild, or moderate 
interference with 
usual social & 
functional 
activities  Itching causing 
inability to 
perform usual 
social & functional 
activities; may 
require 
intervention such 
as antihistamine or 
bathing to provide 
relief  NA 
Vulvar edema  None  Mild, non -pi[INVESTIGATOR_651109], 1 -2+ 
pi[INVESTIGATOR_13034]  3+ pi[INVESTIGATOR_13034], 
severe enough to 
require urinary 
drainage, or 
weepi[INVESTIGATOR_233154] ± 
skin breakdown  
Vulvar erythema  None  Erythema covering 
< 50% of vulvar 
surface  Erythema covering 
≥ 50% of vulvar 
surface  NA 
Vulvar lesions 
(findings seen only 
by [CONTACT_233195])  Normal variants 
includin g skin 
tags, moles, scars, 
etc. Blisters, 
ulcerations, or 
pustules - no 
treatment indicated  Blisters, 
ulcerations or 
pustules, with 
treatment indicated  Severe epi[INVESTIGATOR_651110] (other 
than emergency 
room visit)  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  89 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Vulvar ra sh None  Rash covering < 
50% of vulvar 
surface  Rash covering ≥ 
50% of vulvar 
surface  Severe epi[INVESTIGATOR_651110] (other 
than emergency 
room visit)  
Bartholin’s or 
Skene's gland  No findings  Cyst with no 
inflammation  Cyst or abscess 
with outpatient 
intervention 
indicated  Cyst or abscess 
with 
hospi[INVESTIGATOR_373], (other 
than emergency 
room visit) 
including 
necrotizing 
fasciitis from 
Bartholin’s abscess  
GENITOURINARY SIGNS/SYMPTOMS – VAGINA   
** Note – if vaginal discharge is present both by [CONTACT_651159], only report 
the one with the most severe grade  
Vaginal edema  None  Mild -moderate 
engorgement  Loss of ruggae and 
friability  NA 
Vaginal erythema  None  Erythema covering 
< 50% of vaginal 
surface  Erythema covering 
≥ 50% of vaginal 
surface  NA 
Vaginal dryness  No complaint  Dryness causing 
no or minimal 
interference with 
usual sexual, 
social, & 
functional 
activities  Dryness causing 
greater than 
minimal 
interference with 
usual sexual, 
social, & 
functional 
activities  NA 
 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  90 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 INDIVIDUAL SIGNS/SYMPTOMS  
PARAMETER  GRADE 0         
NORMAL  GRADE 1                
MILD  GRADE 2            
MODERATE  GRADE 3             
SEVERE  
Vaginal discharge 
by [CONTACT_651160] **  Participant's usual 
amount of 
discharge, 
regardless of color 
or quantity  Mild -moderate 
increase in amount 
above participant 
baseline - no 
sanitary protection 
required  Profuse increase in 
discharge requiring 
pad use or other 
hygienic 
intervention  NA 
Vaginal discharge 
as observed by 
[CONTACT_30223] ** (red or 
brown discharge 
should be reported 
under bleeding, not 
discharge)  Slight amount of 
discharge, any 
color  Mild -moderate 
increase in amount  Significant 
increase in amount 
with pooling in 
vagina on 
examination  NA 
Vaginal abras ions 
or lacerations  
(including 
probable applicator 
injuries)  None  Superficial 
disruptions and 
disruptions 
extending through 
the mucosa with 
minimal impact on 
life Large disruptions 
extending through 
the mucosa or 
large superficial 
disruptions, 
hospi[INVESTIGATOR_651111], 
hospi[INVESTIGATOR_373]  (other 
than emergency 
room visit)  
Vaginal lesions 
(findings seen only 
by [CONTACT_651161] b e 
included here)  Normal variants 
including skin 
tags, moles, scars, 
etc. Blisters, 
ulcerations, or 
pustules, no 
treatment indicated  Blisters, 
ulcerations, or 
pustules with 
treatment indicated  Severe epi[INVESTIGATOR_651112] 
(other th an 
emergency room 
visit)  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  91 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Vaginal and 
Cervical masses  
(polyps, myomas, 
or possible 
malignancy)  None or normal 
variants such as 
Nabothian cyst or 
Gartner duct cyst  Polyp or myoma or 
undiagnosed mass 
without symptoms  Polyp, myoma, or 
undiagnosed mass 
causing mild 
symptoms, e.g., 
bleeding/pain not 
requiring more 
than mild 
analgesia  Polyp, myoma, or 
undiagnosed mass 
causing severe 
symptoms, e.g., 
bleeding/pain 
affecting bladder 
and bowel 
function, or visible 
cervical cancer  
GENITOURINARY SIGNS/SYMPTOMS – CERVIX  
Cervical edema 
and friability  None  Edema without 
friability  Friable cervix  NA 
Cervical erythema  None  Erythema covering 
< 50% of cervix  Erythema covering 
≥ 50% of cervix  NA 
Cervical discharge  White or clear 
discharge  Small amount of 
purulent discharge 
at os Purulent discharge 
extending onto 
cervix or vagina  NA 
Visible cervical 
lesions (findings 
seen only by 
[CONTACT_651162])  Normal variants 
including skin 
tags, moles, scars, 
etc. Blisters, 
ulcerations, or 
pustules, no 
treatment indicated  Blisters, 
ulcerations, or 
pustules with 
treatment indicated  NA 
 
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  92 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 INDIVIDUAL SIGNS/SYMPTOMS  
PARAMETER  GRADE 0           
NORMAL  GRADE 1                   
MILD  GRADE 2             
MODERATE  GRADE 3                   
SEVERE  
GENITOURINARY SIGNS/SYMPTOMS – UTERUS  
Uterine 
masses/enlargeme
nt based on 
bimanual 
examination  Normal to 8 week 
size, no palpable 
myomas  Enlarged uterus 
and mild 
symptoms, e.g., 
bleeding/pain 
requiring mild 
analgesics  Enlarged 
uterus/myoma with 
moderate pain or 
symptoms, e.g., 
bleeding  Mass causing 
severe 
bleeding/pain or 
with impact on 
bowel/bladder 
function or 
requires 
transfusion or 
surgery  
Polyp, submucosal 
fibroid, or 
thickened 
endometrium 
detected by 
[CONTACT_226955] (new or 
increasing in size 
from prior exam)  None or 
unchanged/reduce
d in size from prior 
exam  New myomas < 6 
cm diameter 
(single or multiple) 
or diameter 
increased < 6 cm 
since prior exam  New myomas ≥ 6 
cm diameter 
(single or multipl e) 
or diameter 
increased ≥ 6 cm 
since prior exam  Hospi[INVESTIGATOR_059] 
(other than 
emergency room 
visit) and/or 
surgery indicated  
GENITOURINARY SIGNS/SYMPTOMS – ADNEXA  
Not pregnancy - or 
infection -related 
adnexal masses 
based on bimanual 
exam (use if no 
ultrasound done; if 
ultrasound done, 
use ultrasound 
categories below)  None, ≤ 4 cm, 
normal size ovary  > 4 cm with 
minimal or no 
symptoms  > 4 cm with severe 
symptoms, e.g., 
pain, but 
hospi[INVESTIGATOR_7392] (see 
footnote #1)  > 4 cm with severe 
symptom s, e.g., 
pain and 
hospi[INVESTIGATOR_373] (other 
than emergency 
room visit) (see 
footnote #1)  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  93 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 Hydrosalpi[INVESTIGATOR_651113], 
suspected 
hydrosalpi[INVESTIGATOR_651114], but without 
evidence of 
infection or 
ectopic pregnancy  Signs/symptoms of 
infection with 
hospi[INVESTIGATOR_059] 
(other than 
emergency room 
visit) and/or 
surgery indicated  
Adnexal mass 
based on 
ultrasound  None  Simple cyst, 
asymptomatic  Simple cyst, 
symptomatic  Malignant mass 
suspi[INVESTIGATOR_651115] 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  94 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
  
INDIVIDUAL SIGNS/SYMPTOMS  
PARAMETER  GRADE 0  
NORMAL  GRADE 1    
MILD  GRADE 2  
MODERATE  GRADE 3  
SEVERE  
GENITOURINARY SIGNS/SYMPTOMS – ABDOMEN  
Abdominal mass 
not palpable on 
pelvic exam of 
unknown diagnosis  None or known  
(pre-existing) mass 
unchanged in size New mass or 
increased size of 
known mass 
requiring mild 
analgesia with 
minimal impact  New mass or 
increased size of 
known mass with 
moderate 
symptoms  Mass causing 
severe bleeding/ 
pain with impact 
on bladder/bowel 
function or with 
hospi[INVESTIGATOR_059] 
(other than 
emergency room 
visit) indicated or 
malignancy  
GENITOURINARY SIGNS/SYMPTOMS – URINARY TRACT  
Urinary 
frequency  None  Up to 2 times 
participant’s 
normal 
frequency  > 2 times 
participant’s 
normal 
frequency  NA 
Dysuria  None  Superficial 
only Deep ± 
superficial  Inability to void due to pain  
Hematuria  None  Microscopic, 
no 
intervention 
indicated 
(beyond 
evaluation for 
infection)  Gross blood 
in urine or 
medical 
intervention/ 
evaluation 
indicated 
(beyond 
evaluation for 
infection)  Persistent bleeding with transfusion, 
hospi[INVESTIGATOR_059] (other than emergency 
room visit) or intervention indicated to 
obtain hemostasis (endoscopy, 
interventional radiology, or operative)  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  95 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 COMPOSITE SIGNS/SYMPTOMS  
(Use instead of individual categories if 2 or more sig ns/symptoms are present)  
PARAMETER  GRADE 0  
NORMAL  GRADE 1    
MILD           
(Use if all 
signs/ 
symptoms 
would 
individually be  
Grade 0 or 1)  GRADE 2  
MODERATE  
(Use if one or 
more 
signs/symptom
s would 
individually be 
Grade 2 and 
all others 
Grade 0 or 1)  GRADE 3  SEVERE  (Use if 
one or more signs/symptoms 
would  individually  
be Grade 3)  
 
 
NO ORGANISM IDENTIFIED BUT INADEQUATE TESTING PERFORMED  
Vulvovaginitis 
(combinations 
of pain, itching, 
erythema, 
edema, rash, 
tenderness, or 
discharge)  None  Mild 
signs/symptoms  Moderate 
signs/symptoms  Severe signs/  
symptoms  
Cervicitis 
(combinations 
of dyspareunia, 
erythema, 
edema, 
tenderness, and 
discharge)  None  Mild signs/  
symptoms  Moderate signs/  
symptoms  Severe signs/  
symptoms  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  96 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 PID (if 
Gonorrhea or 
Chlamydia 
identified use 
that category)  None  NA Cervicitis with 
mild uterine 
tenderness, ± 
mild cervical 
motion 
tenderness, no 
signs of 
peritoneal 
irritation  More diffuse tenderness, any 
signs of peritoneal irritation, 
or indications for 
hospi[INVESTIGATOR_059] (o ther than 
emergency room visit) 
including  tubo-ovarian abscess  
NO ORGANISM IDENTIFIED AFTER APPROPRIATE TESTING PERFORMED  
Vulvovaginitis 
(combinations 
of pain, itching, 
erythema, 
edema, rash, 
tenderness, or 
discharge)  None  Mild signs/  
symptoms  Moderate signs/  
symptoms  Severe signs/  
symptoms  
Cervicitis 
(combinations 
of dyspareunia, 
erythema, 
edema, 
tenderness, and 
discharge)  None  Mild signs/  
symptoms  Moderate signs/  
symptoms  Severe signs/  
symptoms  
PID (if 
Gonorrhea or 
Chlamydia 
identified use 
that category)  None  NA Cervicitis with 
mild uterine 
tenderness, ± 
mild cervical 
motion 
tenderness, no 
signs of 
peritoneal 
irritation  More diffuse tenderness, any 
signs of peritoneal irritation, 
or indications for 
hospi[INVESTIGATOR_059] (other than 
emergency room visit) 
including tubo -ovarian abscess  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873309] of lesion or 
previous type - 
specific serology, 
covering < 25% of 
vulva, vagina, or 
cervix  Same criteria as 
mild but covering 
25-50% of vulvar, 
vaginal, or cervical 
surface  Same criteria as 
mild but covering 
> 50% of vulvar, 
vaginal, or cervical 
surface and/or 
symptoms of 
significant 
systemic 
involvement, e.g., 
encephalitis, 
hepatitis  
Candida  Absence of 
symptoms 
regardless of 
candida test results  Positive culture, 
wet mount, or 
other laboratory 
test for yeast, with 
mild symptoms  Positive culture, 
wet mount, or 
other laboratory 
test for yeast, with 
moderate to severe 
symptoms  NA 
Trichomonas  Negative  NA Positive wet 
mount, culture, 
PCR or other 
licensed test, 
excluding pap 
smear, showing T. 
vaginalis,  
regardless of 
symptoms  NA 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873310] for Chlamydia, 
asymptomatic or 
with mild uterine 
or cervical moti on 
tenderness (no 
signs of peritoneal 
irritation)  Positive test for 
Chlamydia with 
abdominal or 
uterine or adnexal 
tenderness on 
examination, with 
or without adnexal 
mass, diffuse 
tenderness, any 
signs of peritoneal 
irritation, or 
indications for 
hospi[INVESTIGATOR_18543] 
(other than 
emergency room 
visit) including 
tubo-ovarian 
abscess  
 
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873311] for Gonorrhea, 
asymptomatic or 
with mild uterine 
or cervical motion 
tenderness (no 
signs of peritoneal 
irritation)  Positive test for 
Gonorrhea with 
abdominal or 
uterine or adnexal 
tenderness on 
examination, with 
or without adnexal 
mass, diffuse 
tenderness, any  
signs of peritoneal 
irritation, or 
indications for 
hospi[INVESTIGATOR_059] 
(other than 
emergency room 
visit) including 
tubo-ovarian 
abscess or 
disseminated 
gonococcal 
infection  
Urinary tract 
infection (by 
[CONTACT_651163])  Negative  5-10 WBC/hpf  on 
urinalysis with a 
negative culture 
per protocol 
definition (with or 
without symptoms)  > 10 WBC/hpf on 
urinalysis OR a 
positive culture per 
protocol definition 
(with or without 
symptoms)  Pyelonephritis or 
sepsis (septicemia) 
due to urinary tract 
infecti on 
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  [ADDRESS_873312] or 
both positive with 
known treatment 
and stable titers (< 
4 fold increase)  NA Syphilis diagnosed 
by a positive 
treponemal test 
along with a 
positive non - 
treponemal test 
and no previous 
treatment or  a 
four- fold rise in 
titer on the non -
treponemal test 
after previous 
treatment 
regardless of 
symptoms or non - 
oral lesions 
positive by 
[CONTACT_651164] a 
positive CSF 
VDRL or FTA -
ABS  
GENITAL DYSPLASIA  
Condyloma 
(specify site: 
cervical, vaginal, 
vulvar, perianal)  None  Condylomata 
causing no or mild 
interference with 
daily function  Condylomata 
causing moderate 
interference with 
daily function  Condylomata 
causing severe 
interference with  
daily function, 
secondary 
infection, or 
hospi[INVESTIGATOR_059] 
(other than 
emergency room 
visit) indicated  
  
DMID  Protocol 18-0017  Version 5.0 
SUBVer t 09 Decem ber 2020  
 ________________________________ ________________________________ ________________________________ ______   
 
DMID/NIAID/NIH  101 
CONFIDENTIAL  
DMID eCTD Compliant Interventional Protocol Template and Instructions, Version 4.0, Dated May 18, 2018  
 INFECTIONS AND DYSPLASIA  
PARAMETER  GRADE 0              
NORMAL  GRADE 1                        
MILD  GRADE 2                 
MODERATE  GRADE 3                     
SEVERE  
 
 Intraepi[INVESTIGATOR_651116] (VIN, CIN, 
VAIN)  None  Intraepi[INVESTIGATOR_651117] 1 (IN1)  Intraepi[INVESTIGATOR_651117] 2 (IN2)  Carcinoma in situ 
(CIS) or Invasive 
carcinoma  
Pap (use this 
category only if 
treatment 
performed without 
diagnostic testing, 
otherwise use 
biopsy category 
above)  nl PAP  ASCUS or LSIL  HSIL  Carcinoma in situ 
or carcinoma  
 